dabigatran has been researched along with apixaban in 1003 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (apixaban) | Trials (apixaban) | Recent Studies (post-2010) (apixaban) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 2,405 | 255 | 2,250 |
| Protein | Taxonomy | dabigatran (IC50) | apixaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (1.10) | 29.6817 |
| 2010's | 850 (84.75) | 24.3611 |
| 2020's | 142 (14.16) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, T; Feng, Q; Guo, T; Jia, J; Li, X; Liu, Y; Pei, J; Song, Y; Wu, L; Wu, S; Zhang, Y; Zheng, X | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Gross, PL; Weitz, JI | 1 |
| Harenberg, J; Wehling, M | 1 |
| Turpie, AG | 2 |
| Spyropoulos, AC | 1 |
| Eriksson, BI; Quinlan, DJ; Weitz, JI | 1 |
| Farley, TM; Lewis, D; Macaulay, TE | 1 |
| Lassen, MR; Laux, V | 1 |
| Crain, EJ; Watson, CA; Wong, PC; Xin, B | 1 |
| Ferrandis, R; Llau, JV | 1 |
| Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M | 1 |
| Wittkowsky, AK | 1 |
| Ufer, M | 1 |
| Banda, ZK; Benmira, S; Bhattacharya, V | 1 |
| Bauer, KA | 2 |
| Weitz, JI | 3 |
| Lowenthal, DT; Sattari, M | 1 |
| Adiguzel, C; Walenga, JM | 1 |
| Jiang, X; Wong, PC | 1 |
| Alban, S; Völler, H; Westermann, D | 1 |
| Crowther, M; Lepic, K | 1 |
| Douketis, JD | 1 |
| Morris, TA | 1 |
| Michota, F | 1 |
| Baumhäkel, M; Böhm, M; Schirmer, SH | 1 |
| Ahrens, I; Lip, GY; Peter, K | 1 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Samama, CM | 1 |
| Braunwald, E; Steffel, J | 1 |
| Fisher, WD | 1 |
| Friedman, RJ | 2 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Keltai, K; Keltai, M | 1 |
| Gawaz, M; Geisler, T | 1 |
| Fuster, V; Halperin, JL; Viles-Gonzalez, JF | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Asmis, LM | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Fauchier, L; Le Heuzey, JY; Marijon, E | 1 |
| Mega, JL | 1 |
| Di Pasquale, G; Riva, L | 2 |
| Beer, JH | 1 |
| Galanis, T; Kraft, WK; Merli, GJ | 1 |
| Bode, C; Diener, HC; Kaeufer, T | 1 |
| Heidinger, K; Kemkes-Matthes, B | 1 |
| Breen, KA; Hunt, BJ | 1 |
| Yates, SW | 1 |
| Finsterer, J; Stöllberger, C | 3 |
| Bode, C; Moser, M | 1 |
| Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Godier, A; Lakhdari, M; Martin, AC; Samama, CM | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Goldhaber, SZ | 1 |
| Alpert, JS | 1 |
| Soff, GA | 1 |
| Mahan, C; Spyropoulos, AC | 1 |
| Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Palareti, G; Tripodi, A | 1 |
| Bryer, A | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Cohen, AT | 1 |
| Samama, MM | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Haas, S; Schellong, SM; Spannagl, M | 1 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 2 |
| Bommer, WJ | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Goel, R; Srivathsan, K | 1 |
| Bhatt, DL; Kar, S | 1 |
| Ansell, J; Mantha, S | 2 |
| Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Larsen, TB; Rasmussen, LH; Skjøth, F | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Pollack, CV | 2 |
| Fareed, J; Kalodiki, E; Lewis, B | 1 |
| Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Mangiafico, M; Mangiafico, RA | 1 |
| Harenberg, J; Marx, S; Wehling, M | 1 |
| Zhang, S | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC | 1 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Cannon, CP; Kohli, P | 1 |
| Crockett, MT; Kavanagh, EC; Moynagh, MR | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Kopecky, S | 1 |
| Brenner, B; Hoffman, R | 1 |
| Costopoulos, C; Gorog, DA; Kukreja, N; Niespialowska-Steuden, M | 1 |
| Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Le Heuzey, JY | 1 |
| Tripodi, A | 2 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| Merli, GJ | 1 |
| Brasselet, C; Duval, S | 1 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| Nagler, M; Wuillemin, W | 1 |
| Haschke, M | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Dabitz, R; Ochs, G | 1 |
| Crijns, HJ; Lane, DA; Lip, GY; Nieuwlaat, R; Pisters, R | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Crowther, MA; Siegal, DM | 1 |
| Coccheri, S; Orlando, D | 1 |
| Gulseth, M; Hellwig, T | 2 |
| Eraso, LH; Merli, GJ; Perez, A | 1 |
| Greenspon, AJ | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Graff, J; Harder, S | 2 |
| Garcia, DA; Rojas-Hernandez, CM | 1 |
| Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Connors, JM | 1 |
| Schulman, S | 3 |
| Ageno, W; Bozzato, S; Donadini, MP; Riva, N | 1 |
| Bock, F; Hartung, K; Isermann, B; Meyer, F | 1 |
| Akwaa, F; Spyropoulos, AC | 1 |
| Luettgen, J; White, A; Wong, PC | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Dolgin, E | 1 |
| Roldán Schilling, V; Vicente García, V | 1 |
| Guijarro Merino, R; Villalobos Sánchez, A | 1 |
| Nieto Rodríguez, JA | 1 |
| Hernández, M; Suárez, C | 1 |
| Fernández, D; Heras, M; Penela, D | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Torres, LM | 1 |
| Masjuan, J | 1 |
| Dalmau, FG | 1 |
| Dalla Valle, F; Pesavento, R; Piovella, C; Prandoni, P; Tormene, D | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 2 |
| Holley, AB; King, CS; Moores, LK | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Stiefelhagen, P | 3 |
| Eby, C | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Harris, K; Mant, J | 1 |
| Darius, H; Sommer, S | 1 |
| Gonsalves, WI; Patnaik, MM; Pruthi, RK | 1 |
| Nutescu, EA | 1 |
| Kalus, JS | 1 |
| Arachchillage, DJ; Cohen, H | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Einecke, D | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Aisenberg, J; Desai, J; Granger, CB; Weitz, JI | 1 |
| Klein, HH | 1 |
| Toth, PP | 1 |
| Gong, IY; Kim, RB | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Diener, HC | 1 |
| Douketis, J; Lang, ES; Lazo-Langner, A | 1 |
| Douketis, J; Liew, A | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Baruch, L | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Crowther, MA; Daw, HA; Fawole, A | 1 |
| Páramo, JA | 1 |
| Rider, EB; Rider, OJ | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM | 1 |
| Bhimani, AA; Hong, M | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Chana, F; Llau, JV; Marco, P; Zamorano, JL | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Aguilar, MI; Freeman, WD; Kuo, RS | 1 |
| Bertoletti, L; Da Costa, A; Durupt, S; Epinat, M; Laporte, S; Lega, JC; Mismetti, P | 1 |
| Fanikos, J | 1 |
| Wanat, MA | 1 |
| Avorn, J | 1 |
| Barry, M | 1 |
| Ansell, J; Shameem, R | 1 |
| Lip, GY; Potpara, TS | 2 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Bennaghmouch, N; Ten Berg, JM | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Majeed, A; Schulman, S | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Atar, D; Ghanima, W; Sandset, PM | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Sarode, R; Yates, S | 1 |
| Chandler, WL | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Eikelboom, JW; Kapral, MK; McGrath, ER; O'Donnell, MJ | 1 |
| Degirmenci, SE; Steib, A | 1 |
| Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM | 1 |
| Frölich, L; Harenberg, J; Krejczy, M; Marx, S; Obermann, K; Wehling, M | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Wood, P | 1 |
| Dütsch, M; Klauser, W | 1 |
| Manning, JA | 1 |
| Kitazono, T | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Avram, MJ; Benzon, HT; Bonow, RO; Green, D | 1 |
| Esmon, CT | 1 |
| Barillari, G; Cheng, JW | 1 |
| Crowther, MA; Garcia, DA; Siegal, DM | 1 |
| Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C | 1 |
| Chintala, M; Keohane, C; Li, Q; Ni, W; O'Neill, K; Shang, J; Wang, M; Wei, H | 1 |
| Diener, HC; Weber, R | 1 |
| Bajorek, B; Wang, Y | 1 |
| Goto, S; Tomita, A | 1 |
| Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
| Hanon, O | 1 |
| Rondina, MT; Vazquez, S; Vo, T | 1 |
| Darvish-Kazem, S; Douketis, JD; Liew, A | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Miller, MP; Nordenholz, KE; Trujillo, TC | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Bassand, JP | 1 |
| Arya, R; Couchman, L; Flanagan, RJ; Gous, T; Paradzai, C; Patel, JP | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Fenger-Eriksen, C; Grove, EL; Münster, AM | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Douketis, J; Ing, E | 1 |
| Gislason, G; Sørensen, R | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brieger, D | 1 |
| Cohen, AT; Imfeld, S; Rider, T | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| John, A; Michel, MS | 1 |
| Foley, J; Kirchhof, P; Lip, GY | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Dempfle, CE | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Ahrens, I; Bode, C | 1 |
| Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
| Avendaño-Solá, C; Gómez-Outes, A; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Brinkman, HJ; Dinkelaar, J; Harenberg, J; Leyte, A; Patiwael, S | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Hess, T; Konturek, P | 1 |
| Lévy, S | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Watson, HG | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
| Cowell, RP | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Byrne, RW; Kasliwal, MK; Lopes, DK; Moftakhar, R; Munoz, LF; Panos, NG | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Garg, P; Morris, P; Morris, PD; Saraf, K; Sheridan, P; Storey, R | 1 |
| Barucci, R; Fattirolli, F; Fracchia, S; Mannarino, G; Orso, F; Pratesi, A | 1 |
| Mitchell, AR; Page, PL; Thomas, R | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Donovan, JL; Kanaan, AO; Rollins, BM; Silva, MA | 1 |
| Husted, SE; Thorup, SB; Vang, ML | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT | 1 |
| Boonen, K; Brunsveld, L; Emmen, JM; Schellings, MW; Schmitz, EM; van de Kerkhof, D; van den Heuvel, DJ; van der Graaf, F; van Dongen, JL | 1 |
| Steurer, J | 3 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Moorman, ML; Nash, JE; Stabi, KL | 1 |
| Levy, JH | 2 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Carroll, VS; Frei, J | 1 |
| Lane, DA; Lip, GY; Senoo, K | 1 |
| Crowther, MA; Cuker, A; Garcia, DA; Siegal, DM | 1 |
| Blann, AD; Lip, GY | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Howell, G; Pluym, M | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Dobesh, PP; Fanikos, J | 1 |
| Kovács, T | 1 |
| Ageno, W; Beyer-Westendorf, J | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Cui, J; Li, Z; Liu, C; Wu, B | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Beyer-Westendorf, J | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 2 |
| Gierek, D; Lasek-Bal, A; Urbanek, T | 1 |
| Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y | 1 |
| Deitelzweig, SB; Jing, Y; Makenbaeva, D; Swindle, JP | 1 |
| Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P | 1 |
| Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Peacock, WF | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Du, S; Harenberg, J; Krämer, R; Krämer, S; Wehling, M; Weiss, C | 1 |
| Amin, A; Deitelzweig, S | 1 |
| Blann, AD | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Bultas, J; Karetová, D | 1 |
| Marcus, H; Nandi, D; Tai, D; Vakharia, NN; Vakharia, VN | 1 |
| Berengo, M; Brunello, G; De Biagi, M; Pengo, V; Sivolella, S | 1 |
| Clark, B; Daw, H; Ghobrial, M; Haddad, A; Randhawa, J; Spiro, T; Thiruchelvam, N | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| Garg, P; Ripley, DP | 1 |
| Levasseur-Franklin, KE; Liotta, EM; Naidech, AM | 1 |
| Bultas, J | 1 |
| Bacchus, F; Schulman, S | 1 |
| Cantillon, D; Coleman, CM; Kanj, M; Khalaf, S; Mould, S; Saliba, W; Wazni, O | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Ferreira, J; Mirco, A | 1 |
| Loffredo, L; Perri, L; Violi, F | 2 |
| Oberhofer, E | 1 |
| Powell, JR | 1 |
| Friedman, RJ; Messerschmidt, C | 1 |
| Aleil, B; Krieger, C; Stephan, D | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Bovi, P; Cappellari, M | 1 |
| Greinacher, A; Selleng, K; Thiele, T | 1 |
| Agnelli, G; Prandoni, P; Verso, M | 1 |
| Harenberg, J; Krejczy, M; Lip, GY; Obermann, K; Wehling, M | 1 |
| Bass, AR | 1 |
| Hsieh, CY; Hsu, JC; Lu, CY; Yang, YH | 1 |
| Lane, DA; Wood, K | 1 |
| Blaich, C; Michels, G; Müller, C; Wiesen, MH | 1 |
| Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL | 1 |
| Gehrie, E; Tormey, C | 1 |
| Beyer-Westendorf, J; Breslin, T; NiAinle, F; Werth, S | 1 |
| Cattaneo, M; Lussana, F; Squizzato, A | 1 |
| Hilpert, U | 1 |
| Lip, GY; Proietti, M | 1 |
| Singh, SM; Wijeysundera, HC | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Mani, H; Minet, V; Mullier, F | 1 |
| Agewall, S; Huber, K; Lip, GY; Rubboli, A | 1 |
| Ge, D; Morrill, AM; Willett, KC | 1 |
| Kesteven, P; McCaslin, JE; Robertson, L | 2 |
| Alexander, GC; Barnes, GD; Goldberger, ZD; Lucas, E | 1 |
| Ganetsky, M | 1 |
| Crawford, B; Morimoto, T; Ueda, S; Wada, K | 1 |
| Du, S; Harenberg, J; Krämer, R; Walenga, J; Wehling, M; Weiss, C; Zolfaghari, S | 1 |
| Marietta, M | 1 |
| Bächli, E; Walti, C | 1 |
| Bookhart, B; Crivera, C; Germain, G; Laliberté, F; Lefebvre, P; Martin, S; Nelson, WW; Schein, J | 1 |
| Lane, DA; Lee, SI; Lip, GY; Sayers, M | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Aryal, MR; Donato, AA; Ghimire, S; Giri, S; Jehangir, A; Karmacharya, P; Pathak, R; Poudel, DR; Rettew, A; Shaikh, B | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Russo, F; Spencer, C; Winter, N; Wolf, M; Ziemann, U; Zuern, CS | 1 |
| Rondina, MT; Vazquez, S | 1 |
| Gagg, J; Thachil, J | 1 |
| Buitrago, F; Capilla Lozano, F; Gallego Fuentes, R; Rodríguez Pérez, L | 1 |
| Ang, ES; De Silva, DA; Fabiaña, N; Ramaswami, AP | 1 |
| Athanasakis, K; Bilitou, A; Karampli, E; Kyriopoulos, J; Tsounis, D | 1 |
| Bookhart, B; Crivera, C; Deitelzweig, S; Germain, G; Laliberté, F; Lefebvre, P; Martin, S; McHorney, CA; Nelson, WW; Schein, J | 1 |
| Condliffe, R; Elliot, CA; Hurdman, J; Kiely, DG; Maclean, RM; Quadery, R; Sabroe, I; van Veen, JJ | 1 |
| Heeger, CH; Kuck, KH; Lemes, C; Lin, T; Mathew, S; Metzner, A; Ouyang, F; Plesman, J; Rillig, A; Tilz, RR; Wissner, E; Wohlmuth, P | 1 |
| Ackery, A; Sholzberg, M; Wood, B | 1 |
| Eikelboom, J; Weitz, JI | 1 |
| Riess, H | 1 |
| Cairns, JA; Ciaccia, A; Fisher, WD; Kong, C; Semchuk, W; Turpie, AG; Weitz, JI | 1 |
| Anderson, E; Dyke, C; Glogoza, M; Johnke, K; Leedahl, D; Newman, R | 1 |
| Chan, NC; Dale, BJ; Eikelboom, JW | 1 |
| Goldenberg, NA; Kittelson, JM; Massicotte, MP; Takemoto, CM; Yee, DL | 1 |
| Azimi, N; Forest, CP; Holden, A | 1 |
| Di Minno, A; Di Minno, G; Spadarella, E; Spadarella, G; Tremoli, E | 1 |
| Bouget, J; Oger, E | 1 |
| Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P | 1 |
| Kanorsky, SG; Shevelev, VI | 1 |
| Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M | 1 |
| Forslund, T; Hjemdahl, P; Wettermark, B | 1 |
| Gonzalez, MG; Levy, PD; Peacock, WF; Than, M | 1 |
| Borges, M; Caldeira, D; Costa, J; Fiorentino, F; Gouveia, M; Inês, M; Lopes Pereira, C; Pinheiro, L; Vaz-Carneiro, A | 1 |
| Cuker, A; Siegal, D | 1 |
| Roca, B; Roca, M | 1 |
| Barake, W; Baranchuk, A; Chu, K; Lamb, T; Lamba, J; Marr, JN; McIntyre, WF; Mohajer, K; Oqab, Z; Quadros, K; Quinn, KL; van Oosten, E; Yazdan-Ashoori, P | 1 |
| Bruno, A; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Tate, N; Trocio, J | 1 |
| Bajalan, M; Biggs, TC; Jayaram, S; Mainwaring, J; Salib, R | 1 |
| Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H | 1 |
| McBane, RD; Schaefer, JK; Wysokinski, WE | 1 |
| Noguez, JH; Ritchie, JC | 1 |
| Hussein, A; Saliba, W; Wazni, OM | 1 |
| Didier, R; Escarcega, RO; Kiramijyan, S; Koifman, E; Lipinski, MJ; Torguson, R; Waksman, R | 1 |
| Batson, S; Bird, A; Cohen, AT; Hamilton, M; Liu, X; Mitchell, SA; Phatak, H; Tushabe, D | 1 |
| Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF | 1 |
| Benöhr, P; Hohmann, C; Neumann-Haefelin, T; Radziwill, R | 1 |
| Al-Khalili, F; Benson, L; Lindström, C | 1 |
| Andrade, JG; Ciaccia, A; Connors, S; Krahn, AD; Purdham, D; Skanes, AC | 1 |
| Johnston, S | 1 |
| Amylidi, AL; Exadaktylos, AK; Lehmann, B; Ricklin, ME; Sauter, TC | 1 |
| Adcock, DM; Gosselin, RC | 1 |
| Shao, XH; Wan, HB; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Pastori, D; Perrone, V; Pignatelli, P; Radice, S; Violi, F | 1 |
| Costantinides, F; Maglione, M; Pascazio, L; Rizzo, R | 1 |
| Ammollo, CT; Colucci, M; Dellanoce, C; Incampo, F; Paoletti, O; Semeraro, F; Testa, S | 1 |
| Hansen, PS; Sanchez, R; Walfridsson, H | 1 |
| Alamneh, EA; Bereznicki, LR; Chalmers, L | 1 |
| Smolewski, P; Witkowska, M; Witkowski, M | 1 |
| Greaves, M; Lurie, B; McDonald, L; Olaiya, A; Watson, HG; Watt, B | 1 |
| Caughey, GE; Pratt, NL; Ramsay, EN; Roughead, EE; Shakib, S | 1 |
| Ageno, W; Finazzi, G | 1 |
| Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H | 1 |
| Dobesh, PP; Finks, SW; Trujillo, TC | 1 |
| Ayala-Paredes, F; Birnie, DH; Coutu, B; Coyle, D; Eikelboom, J; Essebag, V; Healey, JS; Kalfon, E; Nery, P; Philippon, F; Sandhu, RK; Sapp, J; Verma, A; Wells, G | 1 |
| Browne, C; Cohen, AT; Hamilton, M; Lanitis, T; Leipold, R; Quon, P; Rublee, D | 1 |
| Alcocer, L | 1 |
| Francart, S; Francis, CW; Gosselin, RC; Gudmundsdottir, BR; Hawes, E; Letertre, LR; Malmstrom, RE; Moll, S; Onundarson, PT; Skeppholm, M | 1 |
| Kaufner, L; Rosenthal, C; Sander, M; von Heymann, C | 1 |
| Blum, RA; Lindfield, D | 1 |
| Acin, F; Bleda, S; Cañibano, C; De Haro, J; Varela, C | 1 |
| Andreotti, F; Arnesen, H; Bachmann, F; Baigent, C; Collet, JP; De Caterina, R; Halvorsen, S; Huber, K; Husted, S; Jespersen, J; Kristensen, SD; Lip, GY; Morais, J; Rasmussen, LH; Ricci, F; Sibbing, D; Siegbahn, A; Storey, RF; Ten Berg, J; Verheugt, FW; Wallentin, L; Weitz, JI | 1 |
| Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Myers, B; Webster, A | 1 |
| Boda, Z | 1 |
| Feng, Y; Li, PJ; Liang, ZA; Liu, GJ; Wang, T; Xiao, J; Yang, Q | 1 |
| Munson, CF; Reid, AJ | 1 |
| Pan, EY; Sobieraj, DM | 1 |
| Baker, D; Narasimhan, S; Wilsmore, B | 1 |
| Harenberg, J | 1 |
| Belik, S; Haslacher, H; Jilma-Stohlawetz, P; Lang, M; Perkmann, T; Quehenberger, P; Ratzinger, F; Schmetterer, KG | 1 |
| Hayes, CJ; Martin, BC; Shah, A; Shewale, A | 1 |
| Marra, A; Perrone, A; Servillo, G; Vargas, M | 1 |
| Kuperan, P; Lee, LH; Ng, HJ; Sum, CL; Tan, CW; Ting, WC; Wong, WH; Yap, ES; Yip, CY | 1 |
| Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y | 1 |
| Pasechnik, IN | 1 |
| Alves Júnior, JL; Fernandes, CJ; Gavilanes, F; Morinaga, LK; Prada, LF; Souza, R | 1 |
| Aronow, WS; Chatterjee, S; Kundu, A; Owan, T; Ryan, JJ; Sardar, P | 1 |
| Martin, K; Moll, S | 1 |
| Bereczki, D; Mirolovics, Á; Papp, C; Zsuga, J | 1 |
| Lesko, LJ | 1 |
| Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG | 1 |
| Bair, TL; Bunch, TJ; Crandall, BG; Cutler, MJ; Day, JD; Jacobs, V; Mallender, C; May, HT; Osborn, JS; Stevens, SM; Weiss, JP; Woller, SC | 1 |
| Arachchillage, DR; Baglin, T; Besser, M; Maclean, R; van Veen, JJ | 1 |
| Boey, JP; Gallus, A | 1 |
| Cappato, R; De Caterina, R; Ezekowitz, MD; Giugliano, RP; Patel, MR; Piccini, JP; Renda, G; Ricci, F; Zimarino, M | 1 |
| Brouns, R; Cornu, P; Desmaele, S; Dupont, AG; Steurbaut, S | 1 |
| Abe, H; Aizawa, Y; Fujii, Y; Jimbo, Y; Sato, M; Takahashi, H; Takano, H | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F | 1 |
| Mizoguchi, T; Yasaka, M | 1 |
| Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW | 1 |
| Chiang, A; Ho, AC; Hong, BK; Hsu, J; Maguire, JI; Rahimy, E; Regillo, CD; Shahlaee, A; Shieh, WS; Sridhar, J | 1 |
| Higashiya, S; Hina, K; Kamikawa, S; Kawamura, H; Komtasubara, I; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Agnelli, G; Becattini, C; Cianella, F; Conti, S; Filippucci, E; Giustozzi, M; Marchesini, E; Pierpaoli, L; Vedovati, MC; Verdecchia, P; Verso, M | 1 |
| Abraham, NS; Bellolio, MF; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT | 1 |
| Bhattacharya, B; Davis, KA; Maung, AA; Schuster, KM | 1 |
| Colquhoun, D; Freedman, SB; Ortiz, M; Simons, LA; Thomas, G; Waterhouse, BJ | 1 |
| Batson, S; Bird, A; Cohen, AT; Hamilton, M; Horblyuk, R; Li, S; Mitchell, SA | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Lamberts, M; Lip, GY; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Hamilton, M; Horblyuk, R; Kamble, S; Keshishian, A; Lip, GY; Mardekian, J; Pan, X | 1 |
| Berger, K; Lesch, CA; Sin, JH | 1 |
| Bruno, A; Kamble, S; Kawabata, H; Lip, GY; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F | 1 |
| Abbate, R; Bassi, L; Carraro, P; Cini, M; Legnani, C; Palareti, G; Paniccia, R; Paoletti, O; Pengo, V; Poli, D; Testa, S; Tripodi, A | 1 |
| Milling, TJ; Spyropoulos, AC | 1 |
| Peacock, WF; Villines, TC | 2 |
| Fanikos, J; Huisman, MV | 2 |
| Kawasugi, K; Kita, H; Kuyama, Y; Shirai, T; Yamamoto, T | 1 |
| Eikelboom, J; Merli, G | 2 |
| Musgrave, KM; Powell, J | 1 |
| Jaffer, IH; Weitz, JI | 1 |
| Granger, CB; Hawkins, NM; Jhund, PS; McMurray, JJ; O'Meara, E; Petrie, MC; Pfeffer, MA; Pozzi, A; Solomon, SD; Swedberg, K; Virani, S; Yusuf, S | 1 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Davies, AH; Lim, CS; Ravikumar, R | 1 |
| Steed, MB; Swanson, MT | 1 |
| Falck, P; Fride Tvete, I; Ghanima, W; Halvorsen, S; Hoxmark, C; Jonasson, C; Solli, O | 1 |
| Bajorek, BV; Pandya, E | 1 |
| Koyfman, A; Long, B | 1 |
| Dyrkorn, R; Lundgaard, H; Molden, E; Spigset, O; Stokes, CL | 1 |
| Barrios, V; Masjuan, J | 1 |
| Bonde, AN; Fosbøl, EL; Gerds, TA; Gislason, GH; Lamberts, M; Lip, GYH; Olesen, JB; Ozenne, B; Staerk, L; Torp-Pedersen, C | 2 |
| Hernandez, I; Smith, KJ; Zhang, Y | 1 |
| Chapman, K; Enjeti, AK; Lim, MS; Swanepoel, P | 1 |
| Brown, JD; Shewale, AR; Talbert, JC | 2 |
| Butala, NM; Kartoun, U; Kennedy, KF; Mahmood, S; Secemsky, EA; Shaw, SY; Wasfy, JH; Yeh, RW | 1 |
| Assar, MD; Ball, T; Cox, KM; McCullough, PA | 1 |
| Keskar, V; Sood, MM | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Al-Kahlili, F; Gilstring, Å; Haeggström, A; Risberg, D; Tullberg, U; Wallén, H | 1 |
| Grove, EL; Hvas, AM; McGrail, R; Nissen, PH; Revsholm, J | 1 |
| Boehr, S; Haen, E | 1 |
| Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA | 1 |
| Douglas, JS; Gauthier-Lewis, ML; Riley, TR; Sanchez, CK | 1 |
| Bhatt, DL; Fonarow, GC; Harding, T; Hernandez, AF; Khan, Y; Peterson, ED; Schwamm, LH; Suter, RE; Xian, Y | 1 |
| Abraham, NS; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Chen, HC; Liu, CY | 1 |
| Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X | 1 |
| Góralczyk, T; Malec, K; Undas, A | 1 |
| Etminan, M; Guo, M; Talany, G | 1 |
| Adelmeijer, J; Bos, S; Boyett, SL; Daita, K; Lisman, T; Potze, W; Sanyal, AJ; Siddiqui, MS | 1 |
| Abraham, NS; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Alban, S; Birschmann, I; Dittrich, M; Eller, T; Flieder, T; Fox, V; Gripp, T; Knabbe, C; Kuhn, J | 1 |
| Biagi, C; Conti, V; Donati, M; Melis, M; Monaco, L; Motola, D; Vaccheri, A; Venegoni, M | 1 |
| Buerke, M; Hoffmeister, HM | 1 |
| Goralczyk, T; Undas, A | 1 |
| Weißbach, L; Zotz, RB | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Bluecher, A; Ferreirós, N; Harder, S; Labocha, S; Meyer Dos Santos, IM; Meyer Dos Santos, S; Picard-Willems, B; Singer, OC | 1 |
| Agnelli, G; Aita, A; Becattini, C; Conti, S; Giustozzi, M; Molini, G; Pierpaoli, L; Valecchi, F; Vedovati, MC; Verdecchia, P | 1 |
| Darius, H | 2 |
| Broscaru, L; Gulba, DC | 1 |
| Terayama, Y | 1 |
| Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Spencer, C; Ziemann, U; Zuern, CS | 2 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Cangemi, DJ; Cipher, DJ; Feagins, LA; Krill, T; Spechler, SJ; Weideman, R | 1 |
| Bliden, KP; Chaudhary, R; Cohen, E; Doubleday, M; Gurbel, PA; Lopez-Espina, CG; Mathew, B; Mohammed, N; Muresan, AA; Raviv, G; Tantry, US; Zaman, F | 1 |
| Brand, S; Crespo, C; Kansal, A; Monreal-Bosch, M; Soulard, S | 1 |
| Gaudio, C; Greco, C; Pelliccia, F; Schiariti, M; Tanzilli, G; Viceconte, N | 1 |
| Carrier, M; de Wit, C; Le Gal, G; Shaw, J | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Blaich, C; Michels, G; Müller, C; Streichert, T; Wiesen, MHJ | 1 |
| Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI | 1 |
| Al Khalili, F | 1 |
| Adachi, T; Fujioka, S; Hoshino, H; Takagi, M | 1 |
| Dell'Aniello, S; Huiart, L; Loo, SY; Renoux, C | 1 |
| Albaladejo, P; Bellamy, L; Bosson, JL; David, JS; de Maistre, E; Gruel, Y; Kauffmann, S; Mémier, V; Pernod, G; Romegoux, P; Samama, CM; Sié, P; Suchon, P; Thoret, S; Viallon, A | 1 |
| Colquhoun, D; Freedman, B; Ortiz, M; Simons, LA; Waterhouse, BJ | 1 |
| Nathwani, S; Wanis, C | 1 |
| Barmparas, G; Bosarge, P; Brown, CV; Bukur, M; Carrick, MM; Catalano, RD; Coimbra, R; Holly-Nicolas, J; Inaba, K; Kaminski, S; Klein, AL; Kobayashi, L; Kopelman, T; Ley, EJ; Martinez, EM; Moore, FO; Murry, J; Nirula, R; Paul, D; Quick, J; Rivera, O; Schreiber, M | 1 |
| Fink, B; Mayer, A; Schuster, P | 1 |
| Ebner, T; Ikukawa, K; Ishiguro, N; Ito, S; Kishimoto, W; Kito, T; Komori, H; Kusuhara, H; Nakanishi, T; Schaefer, O; Tamai, I; Tsuruya, Y; Wang, X; Yamamura, N | 1 |
| Beauchesne, MF; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Turgeon, MH | 1 |
| Bonde, AN; Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Olesen, JB; Sindet-Pedersen, C; Staerk, L | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Langer, F; Voigtlaender, M | 1 |
| Cifu, AS; Jain, A | 1 |
| Churilov, L; Hardidge, AJ; Suen, K; Westh, RN | 1 |
| Abugattas de Torres, JP; Brugada, P; Chierchia, GB; Choudhury, R; Coutino-Moreno, HE; de Asmundis, C; De Regibus, V; Iacopino, S; Longobardi, M; Mugnai, G; Storti, C; Stroker, E; Takarada, K | 1 |
| Asvestas, D; Bazoukis, G; Efremidis, M; Efremidis, T; Georgopoulos, S; Karamichalakis, N; Kolokathis, AM; Letsas, KP; Rokiza, A; Sakellaropoulou, A; Saplaouras, A; Sideris, A; Vlachos, K | 1 |
| Gersh, BJ; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Blennerhassett, R; Favaloro, EJ; Pasalic, L | 1 |
| Gupta, K; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Trocio, J; You, M | 1 |
| Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F | 1 |
| Ansell, J; Fonarow, GC; Gersh, BJ; Hylek, E; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Shrader, P; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q | 1 |
| Kido, K; Scalese, MJ | 1 |
| Antovic, A; Antovic, J; Berndtsson, M; Malmström, RE; Norberg, EM; Rasmuson, A; Skeppholm, M | 1 |
| Andreozzi, GM; Bignamini, AA; Kuca, P; Tomkowski, W | 1 |
| Ashaye, A; Deitelzweig, S; Farmer, C; Hamilton, M; Horblyuk, R; Li, X; Luo, X; Vo, L | 1 |
| Imberti, D; Mastroiacovo, D | 1 |
| Alberts, MJ; Bunz, TJ; Coleman, CI; Peacock, WF | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Køber, L; Lamberts, M; Olesen, JB; Staerk, L; Vinding, NE | 1 |
| Davis, DO; Davis, KA | 2 |
| Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM | 1 |
| Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK | 1 |
| Jolobe, OM | 1 |
| Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ | 1 |
| Jolobe, OMP | 1 |
| Lip, GYH; Rivera-Caravaca, JM | 1 |
| Lip, GYH; Makaritsis, K; Michel, P; Ntaios, G; Papavasileiou, V; Vemmos, K | 1 |
| Ariansen, I; Ellekjær, H; Furu, K; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 2 |
| Alonso, A; Norby, FL | 1 |
| Bell, JS; Dārziņš, P; Fanning, L; Ilomäki, J | 1 |
| Alvarez-Madrazo, S; Bennie, M; Mueller, T; Robertson, C | 1 |
| Valent, F | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Izumiya, Y; Kaikita, K; Kojima, S; Ogawa, H; Sueta, D; Takashio, S; Tsujita, K; Yamabe, H; Yamamoto, E; Yamamuro, M | 1 |
| Douxfils, J; Gosselin, RC | 1 |
| Fogerty, AE; Oertel, LB | 1 |
| Petrasko, M; Petraskova, T; Raizada, A | 1 |
| Koretz, RL | 1 |
| Favaloro, EJ; Lippi, G; Pasalic, L | 1 |
| Bellmann, B; Landmesser, U; Lenz, K; Lin, T; Lsharaf, AK; Nagel, P; Rillig, A; Roser, M; Tscholl, V | 1 |
| Curtice, T; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Luo, X; Mardekian, J; Menges, B; Trocio, J | 1 |
| Abarca, J; Adeboyeje, G; Barron, JJ; Crawford, G; Redberg, R; Rosenberg, A; Sylwestrzak, G; White, J | 1 |
| Ashton, V; Crivera, C; Germain, G; Laliberté, F; Lefebvre, P; McHorney, CA; Peterson, ED; Schein, JR; Wynant, W | 1 |
| Davis, MDP; El-Azhary, RA; King, BJ; McBane, RD; McCarthy, JT; McEvoy, MT; Shields, RC | 1 |
| Izumi, N; Katada, J; Kohsaka, S; Murata, T; Terayama, Y; Wang, F | 1 |
| Hernandez, I; Saba, S; Zhang, Y | 2 |
| Borne, RT; Hess, PL; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Masoudi, FA; O'Donnell, C; Turakhia, MP; Varosy, PD | 1 |
| Carley, B; Draper, E; Griesbach, S; Krueger, K; Larson, T; Parkhurst, B | 1 |
| de Maistre, E; Delavenne, X; Freyburger, G; Golmard, JL; Gouin-Thibault, I; Gruel, Y; Sié, P; Susen, S | 1 |
| Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S | 1 |
| Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ | 1 |
| Griffiths, CL; Hicks, S; Livengood, SJ; Vestal, ML | 1 |
| Akyüz, A; Başaran, Ö; Berilgen, R; Çelik, O; Çetin, N; Coşar, S; Dereli, Y; Doğan, T; Doğan, V; Emren, SV; Enhoş, A; Ergene, O; Gürsul, E; İnci, S; Karaca, I; Karaca, Ö; Köseoğlu, C; Levent, F; Onrat, E; Otlu, YÖ; Özdemir, İH; Özmen, Ç; Sümerkan, M; Zoghi, M | 1 |
| Babiarz, A; Bodys, A; Budnik, M; Filipiak, KJ; Gawałko, M; Kapłon-Cieślicka, A; Kochanowski, J; Opolski, G; Peller, M; Scisło, P; Uliński, R; Żochowski, M | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
| Collings, SL; Evans, D; Hack, G; Johnson, ME; Lefèvre, C; Maguire, A; Stynes, G | 1 |
| Basto, AN; Gibson, CM; Howard, ML | 1 |
| Antia, C; Gloster, H; Hone, N | 1 |
| Boulouis, G; Charidimou, A; Goldstein, JN; Gurol, ME; Morotti, A; Pasi, M | 1 |
| Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S | 1 |
| Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E | 1 |
| Ali, M; Gunasekaran, K; Kaatz, S; Lavender, R; Mahan, CE; Nakhle, A; Paje, DG | 1 |
| Basto, AN; Fewel, NP; Stock, EM; Ta, M; Vo, K | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ | 1 |
| Grove, EL; Hellfritzsch, M; Pottegård, A | 1 |
| Eek, AK; Granas, AG; Øie, E | 1 |
| Gersh, BJ; Nath, KA; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Tangri, N; Yao, X | 1 |
| Brodie, MM; Newman, JC; Rockey, DC; Smith, T | 1 |
| Anguita, M; Asunción Esteve-Pastor, M; Bertomeu, V; Cequier, A; Marín, F; Martínez-Sellés, M; Muñiz, J; Raña Míguez, P; Roldán, I; Ruiz Ortiz, M | 1 |
| Arshad, A; Kaluski, E; Khan, SU; Nasir, F; Riaz, IB; Talluri, S | 1 |
| Anderson, JM; Arnold, DM; Bates, SM; Blostein, M; Caprini, JA; Carrier, M; Clark, NP; Coppens, M; Dentali, F; Douketis, JD; Duncan, J; Gross, PL; Kassis, J; Kowalski, S; Le Gal, G; Le Templier, G; Lee, AY; Li, N; MacKay, E; Schulman, S; Shah, V; Shivakumar, S; Solymoss, S; Spencer, FA; Spyropoulos, AC; Syed, S; Tafur, AJ; Thiele, T; Vanassche, T; Wu, C; Yeo, E | 1 |
| Abdul-Rahim, AH; Acampa, M; Acciarresi, M; Ageno, W; Agnelli, G; Alberti, A; Athanasakis, G; Bandini, F; Becattini, C; Bellesini, M; Bono, G; Bovi, P; Cappellari, M; Carletti, M; Carolei, A; Caso, V; Chiti, A; Chondrogianni, M; Ciccone, A; Cimini, LA; Colombo, G; Consoli, D; Corea, F; D'Amore, C; De Lodovici, ML; Denti, L; Falocci, N; Flomin, Y; Furie, KL; Galati, F; Gialdini, G; Giannini, N; Giorli, E; Giuntini, M; Gourbali, V; Guideri, F; Karagkiozi, E; Karapanayiotides, T; Kargiotis, O; Lanari, A; Lees, KR; Letteri, F; Liantinioti, C; Lorenzini, G; Lotti, EM; Maccarrone, M; Maimone Baronello, M; Makaritsis, K; Mancuso, M; Marcheselli, S; Martini, G; Masotti, L; Monaco, S; Mosconi, MG; Mumoli, N; Ntaios, G; Orlandi, G; Paciaroni, M; Padovani, A; Pezzini, A; Poli, L; Putaala, J; Sacco, S; Scoditti, U; Silvestrelli, G; Sohn, SI; Soloperto, R; Tadi, P; Tassi, R; Tassinari, T; Tatlisumak, T; Tiseo, C; Tomppo, L; Toni, D; Tsivgoulis, G; Vadikolias, K; Vannucchi, V; Venti, M; Yaghi, S; Zedde, M | 1 |
| Engebretsen, EH; Myrstad, M; Tveit, A; Vandvik, I | 1 |
| Cao, F; Henk, HJ; Mardekian, J; Odell, K; Patel, C; Price, K; Sands, GH; Singh, P; Singhal, S; Tan, W; Trocio, J; Tuell, K; Vo, L | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Glynn, RJ; Krumme, AA; Kulldorff, M; Ortiz, AS; Pawar, A; Schneeweiss, S | 1 |
| Ishikawa, T; Moroi, J; Nakase, T | 1 |
| Fujino, T; Hamai, A; Hara, F; Harada, M; Ikeda, T; Kabuki, T; Ohara, H; Wakakura, S | 1 |
| Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM | 1 |
| Chinushi, M; Fuse, I; Hasegawa, Y; Iijima, K; Izumi, D; Minamino, T; Otuki, S; Sato, A; Suda, M; Yagihara, N | 1 |
| Bayer, N; Geidel, S; Hassan, K; Oberhoffer, M; Schlingloff, F; Schmoeckel, M; Wohlmuth, P | 1 |
| Flaujac, C; Golmard, JL; Gouin-Thibault, I; Jabet, A; Joly, BS; Siguret, V; Stepanian, A | 1 |
| Chantarangkul, V; Legnani, C; Testa, S; Tosetto, A; Tripodi, A | 1 |
| Han, F; He, H; Ke, B; Li, X; Li, Y; Zeng, Y | 1 |
| Basic, E; Hohmann, C; Hohnloser, SH; Nabauer, M | 1 |
| Gil, M; Webster, E | 1 |
| Asmar, J; Bizouard, G; Collings, SL; Duhot, D; Fauchier, L; Johnson, ME; Lefèvre, C; Maguire, A; Mouquet, F; Stynes, G; Vannier-Moreau, V | 1 |
| Atar, D; Ghanima, W; König, MSS; Raouf, N; Risnes, K; Rutherford, OW | 1 |
| Ay, C; Königsbrügge, O; Pabinger, I; Quehenberger, P; Weigel, G | 1 |
| Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S | 1 |
| Adcock, DM; Bates, SM; Douxfils, J; Favaloro, EJ; Gosselin, RC; Gouin-Thibault, I; Guillermo, C; Kawai, Y; Kitchen, S; Lindhoff-Last, E | 1 |
| Bączek, M; Gorczyca, I; Jelonek, O; Kośmider, P; Wożakowska-Kapłon, B | 1 |
| Fortier, K; Reebye, UN; Shroff, D | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Antonucci, E; Cosmi, B; Dellanoce, C; Legnani, C; Morandini, R; Palareti, G; Paoletti, O; Pengo, V; Poli, D; Testa, R; Testa, S; Tripodi, A | 2 |
| Howard, LS | 1 |
| Ashley, J; Sood, MM | 1 |
| Dyrkorn, R; Hegstad, S; Lindahl, S; Spigset, O | 1 |
| Koscielny, J; Rosenthal, C; von Heymann, C | 1 |
| de Boer, PT; Hoffmann, M; Jacobs, MS; Levin, LÅ; Postma, MJ; Schouten, JF | 1 |
| Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L | 1 |
| Cheung, JW; D'Amato, S; Gabriels, J; Ip, JE; Khan, M; Lerman, B; Liu, CF; Markowitz, SM; Patel, A; Shaban, N; Singh, P; Thomas, G; Wu, M | 1 |
| Escobar, C; Martí-Almor, J; Martínez-Zapata, MJ; Pérez Cabeza, A | 1 |
| Leow, AS; Loh, JP; Sia, CH; Tan, BY | 1 |
| Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L | 1 |
| Chan, YH; Chang, SH; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wang, CL; Wu, LS; Yeh, YH | 1 |
| Bunz, TJ; Coleman, CI; Martinez, BK; Sood, NA | 1 |
| Armeni, M; Bendini, MG; Caldarone, E; D'Emidio, S; Fusco, A; Leggio, M; Lombardi, M; Mazza, A; Mereu, D; Severi, P | 1 |
| Haas, K; Heuschmann, PU; Khan, S; Purrucker, JC; Rizos, T; Siedler, T; Veltkamp, R; Wolf, M | 1 |
| Dülgeroglu, J; Schmidt, D | 1 |
| Kamble, S; Kawabata, H; Lip, GYH; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Boswell, R; Pearson, GJ | 1 |
| Garzon, J; Jaramillo, L; Mendoza, L; Mendoza-Sanchez, J; Quiroga, A; Rangel, L; Silva, F | 1 |
| Khan, SU; Lash, B; Nasir, F; Raghu Subramanian, C; Wolfe, Z | 1 |
| Hart, A; Shroff, GR; Stoecker, R | 1 |
| Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y | 1 |
| Facchinetti, R; Fantin, F; Ferrari, E; Masciocchi, E; Mazzali, G; Nori, N; Rossi, AP; Sant, S; Zamboni, M; Zoico, E | 1 |
| Ašić, A; Marjanović, D; Mirat, J; Primorac, D | 1 |
| Banach, M; Covic, A; Lopatowska, P; Malyszko, J; Mlodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A | 1 |
| Ageno, W; Antonucci, E; Beyer-Westendorf, J; Morandini, R; Paciaroni, M; Palareti, G; Pengo, V; Poli, D; Righini, M; Sivera, P; Testa, S; Verhamme, P | 1 |
| Alves, JL; Fernandes, CJC; Gavilanes-Oleas, FA; Hoette, S; Jardim, C; Morinaga, L; Prada, LFL; Salibe Filho, W; Souza, R; Terra Filho, M | 1 |
| Jain, N; Reilly, RF | 1 |
| Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
| Kim, M; Kim, MS; Kim, S; Ko, YJ; Lee, J; Park, BJ; Park, K; Yang, BR | 1 |
| Burke, C; Collins, R; Coughlan, T; Egom, EE; McAuliffe, C; McHugh, J; Moore, D; Morrissey, E; O'Brien, J; Pharithi, RB; Ranganathan, D; Ryan, D; Vaughan, M | 1 |
| Bittinger, L; Curtis, C; Pol, D; Ramkumar, S | 1 |
| Durand, M; Johnson, S; Matteau, A; Sinyavskaya, L | 1 |
| Chan, YH; Chang, CY; Chang, SH; Hsieh, MY; Kuo, CF; Kuo, CT; See, LC; Tu, HT; Yeh, YH | 1 |
| Abe, K; Aoyagi, H; Isono, A; Kita, H; Kodashima, S; Kozuma, K; Maruyama, K; Watari, Y; Yamamoto, T | 1 |
| Basalo, MC; Ferrero-Martínez, AI; Gómez-Quintanilla, A; Guitián, A; Montero-Magan, M; Olcoz-Chiva, MT; Paredes-Galán, E; Rodríguez-Artalejo, F; Rodríguez-Pascual, C; Sharma, J; Torres-Torres, I; Vilches-Moraga, A | 1 |
| Barden, S; Campbell, T; Condliffe, R; Connolly, V; Davies, CWH; Donaldson, J; Everett, B; Free, C; Horner, D; Howard, LSGE; Hunter, L; Kaler, J; Nelson-Piercy, C; O-Dowd, E; Patel, R; Preston, W; Sheares, K | 1 |
| Mohebbi, N | 1 |
| Andersson, NW; Lund, M; Melbye, M; Pasternak, B; Svanström, H | 1 |
| Chang, Y; Crowther, M; Holbrook, A; Larsen, TB; Levine, MAH; Li, G; Lip, GYH; Mbuagbaw, L; Sun, X; Tang, J; Thabane, L; Witt, DM | 1 |
| Coupland, C; Hill, T; Hippisley-Cox, J; Vinogradova, Y | 1 |
| Chrapek, M; Janion-Sadowska, A; Papuga-Szela, E; Undas, A; Łukaszuk, R | 1 |
| Azboy, I; Groff, H; Parvizi, J | 1 |
| Krug, K; Laux, G; Peters-Klimm, F; Schwill, S; Szecsenyi, J; van Lieshout, J; Wensing, M | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Bai, Y; Carmo, J; Esteve-Pastor, MA; Lip, GYH; Marín, F; Orenes-Piñero, E; Proietti, M; Rivera-Caravaca, JM; Roldán, V; Romanazzi, I; Romiti, GF | 1 |
| Avnery, O; Battat, E; Derazne, E; Dotan, SG; Ellis, MH; Hammerman, A | 1 |
| Adam, TJ; Alonso, A; Lutsey, PL; MacLehose, RF; Roetker, NS; Zakai, NA | 1 |
| Birschmann, I; Faust, I; Flieder, T; Gripp, T; Hammerschmidt, A; Hendig, D; Knabbe, C; Kuhn, J | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kitazawa, H; Okabe, M; Sato, T; Takahashi, M | 1 |
| Kido, K; Ngorsuraches, S | 1 |
| Bakkehøi, G; Eek, AK; Stenberg-Nilsen, H; Strøm, BO | 1 |
| Calabrese, V; Colaiori, I; Creta, A; Di Sciascio, G; Ioannou, A; Picarelli, F; Providência, R; Ragni, L; Ricciardi, D; Scordino, D | 1 |
| Bowrin, K; Briere, JB; Coleman, C; Fauchier, L; Folkerts, K; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Hirsh Raccah, B; Kalish, Y; Matok, I; Muszkat, M; Perlman, A; Rottenstreich, A; Zacks, N | 1 |
| Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M | 1 |
| Al Yami, MS; Alfayez, OM; Alsheikh, R | 1 |
| Di Lullo, L; Terranova, A; Uguccioni, M | 1 |
| Davani, S; Girard, A; Lagoutte-Renosi, J; Le Poupon, J; Montange, D | 1 |
| Corsi Romanelli, MM; Costa, E; Prinzivalli, M; Rampoldi, B; Sammarco, G | 1 |
| Lip, GYH | 1 |
| Friedecky, D; Hlusi, A; Lukes, J; Nemcova, M; Palova, M; Prochazkova, J; Slavik, L; Ulehlova, J; Vaclavik, J; Zhanelova, M | 1 |
| Barmparas, G; Coimbra, R; Dhillon, NK; Kobayashi, L; Ley, EJ; Margulies, DR; Patel, KA | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Huang, RJ; Jin, C; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B | 1 |
| Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S; Zakai, NA | 1 |
| Aoki, J; Kanamaru, T; Kimura, K; Matsumoto, N; Mishina, M; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Sekine, T; Shimoyama, T; Suda, S; Suzuki, K | 1 |
| Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Rupp, A; Spencer, C; Ziemann, U; Zuern, CS | 1 |
| Braunschweig, F; Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wallén, H | 1 |
| Eckert, R; Fleddermann, A; Hayes, C; Magalski, A; Main, ML; Muskala, P | 1 |
| Abdulsattar, Y; Kamble, S; Lip, GYH; Mardekian, J; Masseria, C; Petkun, W; Phatak, H; Tepper, PG | 1 |
| Lehre, I; Molden, E; Ranhoff, AH; Viktil, KK | 1 |
| Antunovic, M; Dzudovic, B; Dzudovic, J; Obradovic, S; Stavric, M; Subota, V; Subotic, B | 1 |
| Hu, A; Niu, J; Winkelmayer, WC | 1 |
| Carli, G; Chiarini, F; Cortellini, G; Farsi, A; Lippolis, D | 1 |
| Dei, A; Grifoni, E; Landini, G; Masotti, L; Moroni, F; Panigada, G; Spolveri, S; Vannucchi, V | 1 |
| Alvarez-Madrazo, S; Bennie, M; Mueller, T; Robertson, C; Wu, O | 1 |
| Cannegieter, SC; Huisman, MV; Klok, FA; Lijfering, WM; Rosendaal, FR; Teichert, M; Zielinski, GD | 1 |
| Cheon, K; Cho, HJ; Choi, HY; Han, SW; Heo, JH; Jung, YH; Kim, YD; Lee, HS; Lee, KY; Nam, HS; Park, HJ; Park, JH | 1 |
| Ayala-Paredes, F; Becker, G; Birnie, DH; Connolly, SJ; Coutu, B; Eikelboom, J; Essebag, V; Healey, JS; Kalfon, E; Lellouche, N; Nery, PB; Philippon, F; Sandhu, RK; Sapp, J; Sumner, GL; Verma, A; Wells, GA | 1 |
| Dager, WE; Nishijima, DK; Roberts, AJ | 1 |
| Fanaroff, AC; Ohman, EM | 1 |
| Baker, CL; Dhamane, AD; Dina, O; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Rosenblatt, L; Russ, C | 1 |
| Ahmad, A; Evans, A; Oh, K; Petrini, M; Rush, T; Schwartzman, E; Tang, W; Thompson, D; Villines, TC | 1 |
| Ackery, A; Chaudhry, H; Mahamad, S; McFarlan, A; Nisenbaum, R; Rizoli, S; Sholzberg, M | 1 |
| Chung, CP; Daugherty, JR; Dupont, WD; Murray, KT; Ray, WA; Smalley, WE; Stein, CM | 1 |
| Gottsäter, A | 1 |
| Själander, A; Själander, S | 1 |
| Oldgren, J | 1 |
| Strandberg, K | 1 |
| Baser, O; Deitelzweig, S; Friend, K; Gupta, K; Hamilton, M; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Masseria, C; Nadkarni, A; Pan, X | 1 |
| Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M | 1 |
| Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA | 1 |
| Jafari, M; MacKay, J; Stecker, EC; Warden, BA; Willman, A | 1 |
| Campodonico, P; Guiddo, G; Lerza, R; Malerba, M; Minuto, P; Motta, G; Riccardi, A; Spinola, MB | 1 |
| Bae, HJ; Chung, I; Gwak, DS; Han, MK; Kang, JH; Kim, BJ; Kim, BK; Woo, HG | 1 |
| Guo, X; Liu, Y; Sun, Z; Xu, Y; Zhang, Y | 1 |
| Joung, B; Kim, JY; Kim, TH; Kim, YH; Lee, MH; Pak, HN; Park, J; Shim, J; Uhm, JS; Yu, HT | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Garcia, DA; Gu, TM; Sabath, DE | 1 |
| Aslan, U; Aydın, A; Dağdeviren, B; Gürol, T; Kemaloğlu Öz, T; Kobegenova, M; Sarıgül, NU; Soylu, Ö | 1 |
| Banchelli, F; Boriani, G; D'Amico, R; Guazzaloca, G; Magrini, N; Malavasi, VL; Manotti, C; Marietta, M; Pattacini, C; Pavesi, P; Quintavalla, R; Sinigaglia, T; Urbinati, S; Voci, C | 1 |
| Bosch, F; Cerdá, M; Cerezo-Manchado, JJ; Fernández, M; Johansson, E; Martínez, F; Rodríguez, S; Santamaría, A; Varela, A | 1 |
| Rubboli, A | 1 |
| Dibiasi, C; Gratz, J; Wiegele, M | 1 |
| Aldouby-Bier, G; Fisher Negev, T; Hirsh-Raccah, B; Hochberg-Klein, S; Horwitz, E; Kalish, Y; Muszkat, M; Perlman, A | 1 |
| Amiya, R; Higuchi, Y; Hirata, A; Hirayama, A; Kobayashi, T; Sakata, Y; Sotomi, Y | 1 |
| Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R | 1 |
| Young, M | 1 |
| Kopytek, M; Natorska, J; Undas, A; Ząbczyk, M | 1 |
| Ay, C; Beer, R; Haushofer, A; Kwasny, O; Leitgeb, J; Ortler, M; Schaden, E; Schöchl, H; Wiegele, M | 1 |
| Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, SR; Lee, YS; Park, HW; Park, J; Park, JK; Park, JS; Shim, J; Uhm, JS | 1 |
| Chan, YH; Chang, SH; Chen, SW; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Bryk, AH; Chrapek, M; Dębski, M; Desteghe, L; Heidbuchel, H; Janion-Sadowska, A; Konieczyńska, M; Małecka, B; Metzgier-Gumiela, A; Podolec, P; Sadowski, M; Skonieczny, G; Sobieraj, E; Undas, A | 1 |
| Cha, MJ; Choi, EK; Kim, HM; Kwon, JM; Lee, SY; Oh, S; Park, CS | 1 |
| Baranchuk, A; Corbalán, R; Enríquez, A | 1 |
| Deitelzweig, S; Lip, GYH | 1 |
| Brown, JD; Pham, PN | 1 |
| Basic, E; Hohnloser, SH; Nabauer, M | 1 |
| Baldus, S; Hohmann, C; Hohnloser, SH; Jacob, J; Pfister, R; Walker, J | 1 |
| Oo, TH; Rojas-Hernandez, CM | 1 |
| Ferenci, T; Finta, E; Gasparics, R; Medvegy, M; Simonyi, G | 1 |
| Amin, A; Dhamane, A; Di Fusco, M; Friend, K; Garcia Reeves, AB; Keshishian, A; Li, X; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Amin, A; Baker, CL; Carda, E; Dhamane, A; Dina, O; Keshishian, A; Mardekian, J; Nadkarni, A; Rosenblatt, L; Russ, C; Yuce, H | 1 |
| Pickett, JD | 1 |
| Caughey, G; Duszynski, K; Kalisch Ellett, LM; Kerr, M; Pratt, NL; Ramsay, E; Roughead, EE; Shakib, S | 1 |
| Arrigoni, L; Cappelletti, A; Cera, M; Colombo, A; Della Bella, P; Godino, C; Margonato, A; Mattiello, P; Mazzone, P; Melillo, F; Rubino, F; Salerno, A | 1 |
| Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Fleddermann, AM; Hayes, CH; Magalski, A; Main, ML | 1 |
| Boling, B; Nestor, MA | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Imberti, D; Mastroiacovo, D; Pomero, F | 1 |
| Dina, O; Gupta, K; Keshishian, A; Mardekian, J; Nadkarni, A; Shank, TC; Trocio, J; Zhang, Q | 1 |
| Pastori, D; Violi, F | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Aakjaer, M; Andersen, M; Ballarin, E; De Bruin, ML; Droz, C; Gardarsdottir, H; Gasse, C; Groenwold, R; Heeke, A; Huerta, C; Ibáñez, L; Klungel, O; Lassalle, R; Leon-Muñoz, LM; Martin Merino, E; Montero, D; Moore, N; Rottenkolber, M; Sabaté, M; Schmiedl, S; Souverein, P; van den Ham, HA; Vidal, X | 1 |
| Butt, JH; Fosbøl, EL; Garcia, D; Køber, L; Li, A; Peterson, ED; Torp-Pedersen, C; Xian, Y | 1 |
| Behdarvand, B; Bero, L; Karanges, EA | 1 |
| Ariansen, I; Ellekjær, H; Karlstad, Ø; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 1 |
| Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA | 1 |
| Buscarini, E; Coote, N; Droege, F; Dupuis-Girod, S; Fialla, AD; Geisthoff, U; Kjeldsen, A; Lenato, GM; Mager, HJ; Manfredi, G; Millar, CM; Pagella, F; Post, MC; Sabbà, C; Shovlin, CL; Suppressa, P; Sure, U; Torring, PM; Ugolini, S | 1 |
| Agnelli, G; Becattini, C; Isidori, F; Mosconi, MG; Vedovati, MC | 1 |
| Barben, J; d'Athis, P; Manckoundia, P; Menu, D; Mihai, AM; Nuss, V; Putot, A; Rosay, C; Vovelle, J | 1 |
| Balabanova, Y; Brobert, G; Fatoba, S; García Rodríguez, LA; Martín-Pérez, M; Roberts, L; Ruigomez, A; Schaefer, B; Suzart-Woischnik, K; Vora, P | 1 |
| Löser, C; Nast, A; Zeymer, U | 1 |
| Balabanova, Y; Brobert, G; Fatoba, S; Fernandez, O; García Rodríguez, LA; Roberts, L; Ruigómez, A; Vora, P | 1 |
| Beauchesne, LM; Bouma, BJ; Khairy, P; Macle, L; Mongeon, FP; Mulder, BJM; Schwerzmann, M | 1 |
| Barequet, IS; Bourla, N; Moisseiev, J; Salomon, O; Tamarin, I; Zehavi-Dorin, T | 1 |
| Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ | 1 |
| Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK | 1 |
| Aboutanos, M; Anand, RJ; Bachmann, L; Bennett, JD; Broering, B; Chenault, G; Chou, C; Contaifer, D; DeAntonio, JH; Doan, D; Feeser, VR; Ferrada, P; Goldberg, S; Han, J; Hobgood, S; Jayaraman, S; Kumar, NG; Leichtle, SW; Liebrecht, L; Mangino, M; Nguyen, T; Procter, LD; Rodas, EB; Rossi, AP; Staschen, J; Vitto, MJ; Whelan, JF; Wijesinghe, DS; Wolfe, L; Young, C | 1 |
| Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Bailey, E; Bollu, PC; Dyer, N; Govindarajan, R; Nagarajan, E; Sivaraman, M; Yelam, A | 1 |
| Alonso, A; Chen, LY; Diem, SJ; Ensrud, KE; Lutsey, PL; MacLehose, RF; Norby, FL | 1 |
| Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH | 1 |
| Carlucci, G; Carlucci, M; Ferrone, V; Fontana, A; Milanetti, E; Todaro, S; Ventrella, A | 1 |
| Jansson, M; Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Bartels, DB; Gopalakrishnan, C; Gurusamy, VK; Huybrechts, KF; Landon, J; Schneeweiss, S; Zint, K | 1 |
| Chao, HC; Jeng, JS; Jhang, RS; Kuo, CH; Liao, HW; Lin, SY; Lin, YT; Peng, YF; Tang, SC; Tsai, IL | 1 |
| Hsu, JY; Huang, HK; Lin, SM; Liu, PP; Loh, CH; Peng, CC; Wang, JH; Yeh, JI | 1 |
| Drabik, L; Potpara, T; Undas, A | 1 |
| Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F | 1 |
| Boissier, E; Bourcier, R; Dargazanli, C; Desal, H; Gory, B; Kyheng, M; L'Allinec, V; Labreuche, J; Lapergue, B; Mazighi, M; Roy, M; Sibon, I | 1 |
| Aimo, A; De Caterina, R; Petricciuolo, S | 1 |
| Buda, S; Degli Esposti, L; Perrone, V; Piovaccari, G; Saragoni, S | 1 |
| Albert, L; Bejjani, A; Coons, JC; Iasella, CJ | 1 |
| Alves, G; Bicker, J; Falcão, A; Fortuna, A; Gouveia, F; Rocha, M; Santos, J | 1 |
| Ali, H; Hanley, DF; Marsh, EB; Nyquist, PA; Shin, SS; Ziai, WC | 1 |
| Chin, PKL; Moore, GA; Zhang, M | 1 |
| Brčić, M; Ćelap, I; Margetić, S; Mihić, R | 1 |
| Albrecht, H; Hagel, AF; Konturek, PC; Maass, LS; Neurath, MF; Raithel, M | 1 |
| Ho, KH; Leng, G; van Hove, M | 1 |
| Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A | 1 |
| Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S | 1 |
| Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG | 1 |
| Agosti, S; Di Brigida, G; Morelli, N; Risso, R; Rota, E; Rovere, ME; Testa, L | 1 |
| Ageno, W; Casella, IB; Chee, KH; Desch, M; Donado, E; Goldhaber, SZ; Reilly, PA; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Ashley, J; Badve, SV; Battistella, M; Bota, S; Garg, AX; Harel, Z; Jun, M; Manuel, D; Mavrakanas, T; McArthur, E; Molnar, AO; Rhodes, E; Sood, MM; Tanuseputro, P; Wells, P | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A | 1 |
| Brooks, MM; Glynn, NW; Hernandez, I; Saba, S; Yang, L; Zhang, Y | 1 |
| Chan, EW; Cheung, CL; Lam, JKY; Lau, WCY; Lee, ACH; Lip, GYH; Man, KKC; Sing, CW; Siu, CW; Wong, ICK | 1 |
| Branam, DL; Covert, K | 1 |
| Alexandre, J; Chrétien, B; Dolladille, C; Fedrizzi, S; Lelong-Boulouard, V; Sassier, M | 1 |
| Son, KB | 1 |
| Blais, JE; Chan, EW; Chen, EYH; Chui, CSL; Lau, WCY; Mok, MT; Seto, WK; Suh, IH; Wong, ICK; Yan, VKC; Zhao, J | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Pazan, F; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Douketis, J; Kaplovitch, E; Shaw, JR | 1 |
| Carrier, M; Clark, EG; Garg, AX; Harel, Z; Hill, K; Hundemer, GL; Knoll, G; McArthur, E; Rhodes, E; Sood, MM; Sucha, E | 1 |
| Abdelmaseeh, P; Asinger, R; Megaly, M; Sedhom, R | 1 |
| Budnik, M; Chrapek, M; Filipiak, KJ; Gawałko, M; Gielerak, G; Gorczyca, I; Jelonek, O; Jurek, A; Kapłon-Cieślicka, A; Kiliszek, M; Kochanowski, J; Krzesiński, P; Michalska, A; Opolski, G; Scisło, P; Starzyk, K; Uziębło-Życzkowska, B; Wożakowska-Kapłon, B | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, AL; Keshishian, AV; Li, X; Lip, GYH; Luo, X; Mardekian, J; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Le, T; Pasciolla, S; Wright, K; Zizza, LF | 1 |
| Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
| Bardou, M; Billionnet, C; Drouin, J; Maura, G; Neumann, A; Weill, A | 1 |
| As-Sultany, M; Donnachie, NJ; Finley, R; Highcock, AJ | 1 |
| Doyama, H; Fujishiro, M; Fujita, T; Hasatani, K; Hatta, W; Hiasa, Y; Hikichi, T; Igarashi, K; Iguchi, M; Inoue, T; Kawaguchi, K; Kitamura, K; Kuribayashi, S; Mikami, T; Morita, Y; Nishida, T; Nishikawa, J; Oda, I; Sumiyama, K; Sumiyoshi, T; Tomida, H; Tsuji, Y; Uraoka, T; Yada, T; Yamamoto, K; Yanagitani, A; Yoshio, T | 1 |
| Lobastov, KV; Schastlivtsev, IV | 1 |
| Bakker, ECMD; Borst, JM; Bosma, LBE; Hudig, F; Mairuhu, ATA; Rier, M; van Rein, N; Visser, LE; Vukadin, N; Wilms, EB | 1 |
| Bane, KL; Maji, D; Mohseni, P; Opneja, A; Stavrou, EX; Suster, MA; Wilson, BM | 1 |
| Cao, ZC; Dong, Y; Huang, ZC; Jia, HY; Li, CQ; Liu, TL; Liu, XY; Sun, JJ | 1 |
| Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP | 2 |
| Cui, Y; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 1 |
| Goya, M; Hirao, K; Kawabata, M; Maeda, S; Sasano, T; Takahashi, Y; Yagishita, A | 1 |
| Dannenberg, L; Hohlfeld, T; Kelm, M; Orban, M; Petzold, T; Polzin, A; Thienel, M; Wolff, G; Zeus, T | 1 |
| Brüggenjürgen, B; Darius, H; De Caterina, R; Duytschaever, M; Huber, K; Kirchhof, P; Kotecha, D; Le Heuzey, JY; Lucerna, M; Patti, G; Pecen, L; Renda, G; Ricci, F; Rohla, M; Schilling, RJ; Schnabel, RB; Sellal, JM; Siller-Matula, JM; Verheugt, FWA; Wachter, R; Zamorano, JL | 1 |
| Caprini, JA; Clark, NP; Douketis, J; Kaplovitch, E; Li, N; MacDougall, K; Schulman, S; Spyropoulos, AC; Tafur, AJ | 1 |
| Eikelboom, JW; Eriksson, N; Ezekowitz, MD; Granger, CB; Hijazi, Z; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A | 1 |
| Aakjaer, M; Andersen, M; Ballarín, E; De Bruin, ML; Gardarsdottir, H; Gasse, C; Gerlach, R; Huerta, C; Ibánez, L; Klungel, O; Leon-Muñoz, LM; Martin Merino, E; Montero, D; Rottenkolber, M; Sabaté, M; Schmiedl, S; Souverein, PC; Tauscher, M; van den Ham, R; Vidal, X | 1 |
| Hocker, TLH; Neill, BC; Singh, AH; Siscos, SM | 1 |
| Haas, S; Patti, G | 1 |
| Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B | 1 |
| Cho, HJ; Choi, HY; Choi, S; Jang, HJ; Jang, SS; Jeon, S; Kim, DE; Kim, H; Kim, J; Kim, K; Kim, YD; Kwon, IC; Lee, KY; Lee, SK; Nahrendorf, M; Ryu, WS; Schellingerhout, D | 1 |
| Bereznicki, LR; Bezabhe, WM; Curtain, C; Peterson, GM; Radford, J; Salahudeen, MS; Wimmer, BC | 1 |
| Chan, N; Eikelboom, JW; Sobieraj-Teague, M | 1 |
| Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Rome, BN | 1 |
| Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Jiang, YR; Liao, JN; Tsai, CT | 1 |
| Lorenzoni, V; Pirri, S; Turchetti, G | 1 |
| Chen, S; Dong, Y; He, J; Lip, GYH; Liu, C; Wu, D; Ye, Z; Zhu, W | 1 |
| Chan, FK; Guo, CL; Lam, KL; Lau, LH; Mak, JW; Ng, SC; Wong, GL; Wong, SH; Yip, TC | 1 |
| Côté, R; Dorais, M; Martel, MJ; Perreault, S; Qazi, JZ; Schnitzer, ME | 1 |
| Luna, JD; Manzano-Gamero, V; Pardo-Cabello, AJ | 1 |
| Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
| De Souza, S; Goddard, R; Hargreaves, IP; Porter, KMF | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Chan, EWY; Cheung, BMY; Cheung, CL; Lau, WCY; Li, GHY; Lip, GYH; Sing, CW; Tan, KCB; Wong, ICK | 1 |
| Barnes, GD; Cuker, A; Dawwas, GK; Dietrich, E; Leonard, CE; Lewis, JD | 1 |
| Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL | 1 |
| Munasinghe, A; Rao, V | 1 |
| Pos, L | 1 |
| Cuccia, C; Enea, I; Fresco, C; Paciaroni, M; Patti, G; Pecora, D; Rocca, B; Rubboli, A | 1 |
| Daei, M; Heidari, Z; Khalili, H | 1 |
| Anderson, A; Eworuke, E; Gassman, A; Hou, L; Huang, TY; Moeny, D; Waldron, P; Wong, HL; Zhang, R | 1 |
| Bradley, SM; Gosch, KL; Hess, PL; Jani, SM; Maddox, TM; Michael Ho, P; Varosy, PD; Virani, SS | 1 |
| Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A | 2 |
| Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J | 1 |
| Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M | 1 |
| Dilcher, B; Hayward, I; Kline, J; Pagenhardt, J; Quedado, K | 1 |
| Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM | 1 |
| Bolek, T; Galajda, P; Kamenišťáková, A; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J | 1 |
| Giacomuzzi, K; Jani, E; Marschang, P; Mueller, T; Thuile, K | 1 |
| Bessette, LG; Gagne, JJ; Glynn, RJ; Kim, DH; Lee, H; Pawar, A; Schneeweiss, S | 1 |
| Ikusaka, M; Ishizuka, K; Mori, T; Yokokawa, D | 1 |
| Badve, SV; Beaubien-Souligny, W; Blum, D; Dorian, P; Garg, AX; Harel, Z; Jandoc, R; Jeyakumar, N; Jun, M; Kitchlu, A; McArthur, E; Silver, SA; Smyth, B; Sood, MM; Wald, R; Yan, AT | 1 |
| Chen, J; Chen, M; Fang, Z; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 1 |
| Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Ma, L; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 1 |
| Aoyama, T; Enomoto, A; Kawano, Y; Mano, Y; Nagata, M; Nishikawa, T; Sasaki, Y; Takahashi, H | 1 |
| Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S | 1 |
| Barnes, GD; DeCamillo, D; Haymart, B | 1 |
| Fukuoka, H; Hoshida, S; Inoue, S; Inui, H; Minamisaka, T; Mine, K; Shinoda, Y; Tachibana, K; Ueno, K; Watanabe, T | 1 |
| Ágústsson, AS; Björnsson, ES; Guðmundsdóttir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Önundarson, PT; Pálsson, DA; Reynisson, IE; Rumba, E | 1 |
| Avery, P; Biss, T; Kamali, F; Kampouraki, E; Wynne, H | 1 |
| Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L | 1 |
| Abe, K; Amano, H; Asaoka, Y; Honda, T; Kodashima, S; Komatsuda, S; Kozuma, K; Manabe, D; Tanaka, A; Yamamoto, H; Yamamoto, T; Yanagisawa, D | 1 |
| Alvarez, P; Chaudhury, P; Desai, MY; Hanna, M; Kanj, M; Mentias, A; Moudgil, R; Nakhla, M | 1 |
| Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C | 1 |
| Huang, CF; Huang, TM; Jeng, JS; Kuo, CH; Lin, SY; Peng, YF; Tang, SC | 1 |
| Jaffray, J; Young, G | 1 |
| Lomakina, V; Sozio, SJ; Tekle, J | 1 |
| Barnes, GD; Connors, JM; Cuker, A; Dawwas, GK | 1 |
| Bertoletti, L; Bin, V; Delavenne, X; Hodin, S; Lafaie, L; Saïb, S | 1 |
| Murray, KT; Ray, WA | 1 |
| Gu, HQ | 1 |
| Chan, ECY; Soh, XQ; Tan, DS | 1 |
| Foderà, E; Intrieri, M; La Floresta, P; Martucci, G; Medoro, A; Mignogna, D; Passarella, D; Porcile, C; Raimo, G; Russo, C | 1 |
| Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Guitard-Dehoux, D; Hanon, O; Jacoud, F; Mahé, I; Marant-Micallef, C; Née, M; Steg, PG; Van Ganse, E | 1 |
| Ali, AK; Duffield, S; Gatto, N; Gibbs, L; Govil, P; Jaksa, A; Jonsson, P; Kent, S; Kincaid, L; Patrick, AR; Rowark, S; Sharma, M | 1 |
| Brewster, J; Hingorani, AD; Lau, WCY; Li, J; Lip, GYH; Man, KKC; Reich, C; Seager, S; Stewart, HM; Torre, CO; Van Zandt, M; Wei, L; Wong, ICK | 1 |
| Kalka, I; Kornowski, R; Rossman, H; Segal, E; Talmor-Barkan, Y; Witberg, G; Yacovzada, NS | 1 |
| Buonocore, M; Degezelle, K; Meyns, B; Rex, S | 1 |
| Curis, E; Delrue, M; Foulon-Pinto, G; Gaussem, P; Gouin-Thibault, I; Guen, JL; Jourdi, G; Ketz, F; Lafuente-Lafuente, C; Lecompte, T; Mullier, F; Pautas, E; Puymirat, E; Rivière, L; Siguret, V; Tall, F | 1 |
| Matre, NB; McLaughlin, EM; Naik, KD; Rozycki, AJ; Whitson, BA | 1 |
| Nakano, Y; Sairaku, A | 1 |
| Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
| Angelini, A; Ballarini, M; Dalmastri, V; Grammatico, F; La Manna, G; Minerva, V; Pizzini, AM; Silingardi, M; Todeschini, P | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Baiardi, G; Cafaro, A; Cangemi, G; Caviglia, MC; Mattioli, F; Poeta, MG; Stella, M | 1 |
| Chilbert, MR; Goriacko, P; Jacobs, D; Saber, M; Sinnet, M; Woodruff, AE | 1 |
437 review(s) available for dabigatran and apixaban
| Article | Year |
|---|---|
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
Topics: Fibrinolytic Agents; Humans; Molecular Structure; Thrombosis | 2022 |
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
New anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Morpholines; Oligosaccharides; Postphlebitic Syndrome; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism | 2008 |
The top 4 advances in antithrombotic care in the last year.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Brave new world: the current and future use of novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2008 |
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.
Topics: Animals; Antithrombin III; Benzimidazoles; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2009 |
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
New anticoagulants and regional anesthesia.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Benzimidazoles; Dabigatran; Hematoma, Epidural, Spinal; Humans; Morpholines; Nerve Block; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2009 |
New anticoagulants for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K | 2009 |
New oral anticoagulants: a practical guide for clinicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Evidence-Based Medicine; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2010 |
Old versus new anticoagulants: focus on pharmacology.
Topics: Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2010 |
New oral anticoagulants in development: potential for improved safety profiles.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Evaluation; Factor Xa; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2010 |
Potential of new anticoagulants in patients with cancer.
Topics: Anticoagulants; Benzimidazoles; Biotin; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2010 |
Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Drug Approval; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; United States; Venous Thrombosis | 2011 |
Drug and dietary interactions of the new and emerging oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
[New oral anticoagulants: better than vitamin K antagonists?].
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K | 2010 |
New anticoagulants for the prevention of thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drugs, Investigational; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Intracerebral hemorrhage: Pick your poison.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Humans; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Venous Thromboembolism; Warfarin | 2010 |
[Novel anticoagulants for stroke prevention in atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2010 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2011 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
New anticoagulants for prevention of stroke in patients with atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
Rivaroxaban for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Neurosurgical Procedures; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stockings, Compression; Surgical Procedures, Operative; Thiophenes; Urologic Surgical Procedures; Venous Thrombosis | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2011 |
[New anticoagulants. Characteristics, monitoring and management of bleeding].
Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2011 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin | 2011 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2012 |
Improving prevention and treatment of venous thromboembolism: clinical trial results.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Newer oral anticoagulant agents: a new era in medicine.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants in the ED setting: a review.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Benzoates; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The novel oral anticoagulants: an update for the interventional radiologist.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Radiography, Interventional; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Novel oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants for atrial fibrillation: a neurologist's view].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Laboratory tests and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Morpholines; Predictive Value of Tests; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes | 2012 |
The laboratory and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Hemostasis; Humans; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Food-Drug Interactions; Hemostasis; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Switzerland; Thiophenes; Thromboembolism | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
New oral therapies for the prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism | 2013 |
The novel oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coumarins; Dabigatran; Female; Hematology; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Sex Factors; Warfarin | 2013 |
[From heparin to apixaban: anticoagulants cut both ways?].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; International Normalized Ratio; Liver Failure; Metabolic Clearance Rate; Morpholines; Perioperative Care; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Vitamin K | 2014 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[New approaches in the treatment of deep vein thrombosis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2012 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Withholding Treatment | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes | 2012 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; Biotin; Dabigatran; Humans; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Thiazoles; Venous Thromboembolism; Vitamin K | 2013 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2013 |
Novel anticoagulants and laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
The new oral anticoagulants in clinical practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Use of new oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Breast Feeding; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Monitoring; Female; Humans; Infant, Newborn; Maternal Exposure; Morpholines; Pregnancy; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in gastroenterology practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Hemostatic Techniques; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
The changing face of oral anticoagulants.
Topics: Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prodrugs; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
[New clinical perspectives in the management of oral direct anticoagulant agents].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2014 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhagic Disorders; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Novel oral anticoagulants: a focused review for stroke physicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Child; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation Tests; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Hematoma, Epidural, Spinal; Humans; Morpholines; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Topics: Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulants and regional anaesthesia.
Topics: Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Targeting factor Xa and thrombin: impact on coagulation and beyond.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Atherosclerosis; Benzimidazoles; Blood Coagulation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Evaluation, Preclinical; Factor Xa; Humans; Inflammation; Pyrazoles; Pyridines; Pyridones; Receptors, Proteinase-Activated; Thrombin; Thrombosis | 2014 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Current state of anticoagulants to treat deep venous thrombosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2014 |
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2014 |
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Vitamin K | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants and oculoplastic surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cataract Extraction; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgery, Plastic; Thiophenes | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Outcome Assessment, Health Care; Patient Acuity; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thrombosis | 2015 |
Oral direct inhibitors of coagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants: integration into clinical practice.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism; Vitamin K; Warfarin | 2014 |
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Atrial fibrillation - new frontiers in anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Warfarin | 2014 |
[Monitoring options and reversal agents for oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2014 |
Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Hemorrhage; Humans; Pyrazoles; Pyridones; Risk Factors | 2014 |
Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Wounds and Injuries | 2014 |
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Management of hemorrhage with the target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Target-specific oral anticoagulants and the hospitalist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Hospitalists; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis; Warfarin | 2015 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2015 |
New oral anti-coagulants: Implications for neurosurgery.
Topics: Animals; Anticoagulants; Dabigatran; Hemorrhage; Humans; Neurosurgery; Pyrazoles; Pyridones; Warfarin | 2015 |
Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dental Care for Chronically Ill; Factor Xa Inhibitors; Humans; Oral Hemorrhage; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2015 |
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Dabigatran; Drug Interactions; Humans; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2014 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2015 |
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cerebral Hemorrhage; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Endovascular Procedures; Factor Xa Inhibitors; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thrombectomy; Thrombolytic Therapy; Tissue Plasminogen Activator | 2015 |
Reversal of anticoagulants: an overview of current developments.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzamides; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostatics; Heparin; Humans; Infusions, Parenteral; Intracranial Hemorrhages; Polysaccharides; Protamines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombosis; Vitamin K | 2015 |
Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Orthopedic Procedures; Postoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism; Vitamin K | 2015 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Postoperative Complications; Postoperative Hemorrhage; Prothrombin; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2015 |
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.
Topics: Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinations; Factor Xa Inhibitors; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Stents; Thrombosis; Ticlopidine; Warfarin | 2015 |
Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Topics: Administration, Oral; Antithrombins; Azetidines; Benzylamines; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thrombosis | 2015 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2015 |
Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Female; Heparin, Low-Molecular-Weight; Humans; Male; Odds Ratio; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Survival Analysis; Treatment Outcome; Venous Thromboembolism | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.
Topics: Anticoagulants; Dabigatran; Emergency Medicine; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United Kingdom | 2015 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Treatment of bleeding complications due to oral anticoagulant drugs].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2015 |
Laboratory measurement of the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2015 |
Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Proton Pump Inhibitors; Pyrazoles; Pyridones; Warfarin | 2015 |
Treatment of pulmonary embolism.
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Target-specific Oral Anticoagulants in the Emergency Department.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2015 |
Monitoring and reversal of direct oral anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time | 2015 |
The new oral anticoagulants: Reasonable alternatives to warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis | 2015 |
A guide to new anticoagulant medications for ENT surgeons.
Topics: Administration, Oral; Adult; Anticoagulants; Clinical Competence; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Otolaryngology; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Surveys and Questionnaires; United Kingdom | 2015 |
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Vitamin K | 2016 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2016 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; Hemorrhage; Humans; Ligation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Defibrillators, Implantable; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Thiazoles; Warfarin | 2016 |
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Novel oral anticoagulants--issues in clinical practice].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis | 2015 |
An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery.
Topics: Administration, Oral; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
The laboratory's 2015 perspective on direct oral anticoagulant testing.
Topics: Administration, Oral; Algorithms; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Calibration; Chemistry, Clinical; Dabigatran; Dose-Response Relationship, Drug; Humans; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Prothrombin; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Medication Errors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[The latest recommendations on the use of new oral anticoagulants in routine practice].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2016 |
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; United Kingdom; Venous Thromboembolism | 2016 |
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drugs, Investigational; Evidence-Based Medicine; Humans; Mexico; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2016 |
Management of direct oral anticoagulants-associated bleeding in the trauma patient.
Topics: Administration, Oral; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Clinical Protocols; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; Wounds and Injuries | 2016 |
Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Humans; Ischemia; Leg; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Coronary Artery Disease; Dabigatran; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Direct oral anticoagulants: a guide for daily practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
[Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Severity of Illness Index; Surgical Procedures, Operative; Thiazoles | 2016 |
Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Causality; Comorbidity; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thromboembolism; Treatment Outcome; Vitamin K | 2016 |
Novel oral anticoagulants in plastic surgery.
Topics: Administration, Oral; Algorithms; Anticoagulants; Dabigatran; Elective Surgical Procedures; Emergencies; Humans; Kidney; Liver; Perioperative Care; Plastic Surgery Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Outpatients; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Characteristics; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Bleeding management in patients with new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore.
Topics: Antithrombins; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Practice Guidelines as Topic; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Singapore | 2016 |
[The use of new oral anticoagulants in surgery. Part 1].
Topics: Anticoagulants; Dabigatran; Humans; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative | 2016 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Minimizing the Risk of Bleeding with NOACs in the Elderly.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Precision Medicine; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
[THE IMPORTANCE OF ANTICOAGULANT THERAPY IN PATIENTS WITH ARTIAL FIBRILLATION IN STROKE PREVENTION--SUMMARY OF INTERNATIONAL DATA AND NOVEL THERAPEUTIC MODALITIES].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prevalence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2016 |
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Drug Treatment of Venous Thromboembolism in the Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2016 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Anticoagulation for patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thrombolytic Therapy; Warfarin | 2016 |
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2016 |
Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Long-Term Care; Network Meta-Analysis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Venous Thromboembolism | 2016 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban | 2016 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative | 2016 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
A systematic review of anti-thrombotic therapy in epistaxis.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Clopidogrel; Dabigatran; Disease Management; Epistaxis; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Ticlopidine; Tranexamic Acid; Warfarin | 2016 |
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials, Phase III as Topic; Coagulants; Dabigatran; Humans; Patient Safety; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Catheters, Indwelling; Dabigatran; Drug Administration Schedule; Drug Dosage Calculations; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hemostasis, Surgical; Humans; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles | 2016 |
Bleeding with direct oral anticoagulants vs warfarin: clinical experience.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Safety of direct oral anticoagulants: insights from postmarketing studies.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Best Clinical Practice: Current Controversies in Pulmonary Embolism Imaging and Treatment of Subsegmental Thromboembolic Disease.
Topics: Anticoagulants; Dabigatran; Decision Making; Humans; Patient Outcome Assessment; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2017 |
Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles | 2017 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2016 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
Role of agents for reversing the effects of target-specific oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Dabigatran; Drug Evaluation; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Loss, Surgical; Dabigatran; Drug Interactions; Half-Life; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiazoles; Thromboembolism; Vitamin K | 2017 |
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2017 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin | 2017 |
[New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome | 2017 |
Novel oral anticoagulants and exodontia: the evidence.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Oral Surgical Procedures; Postoperative Hemorrhage; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016).
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Consensus; Dabigatran; Delphi Technique; Europe; Evidence-Based Practice; Female; Humans; Long-Term Care; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Stroke; Thiazoles; Warfarin | 2017 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2017 |
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Novel (Oral) Anticoagulant Challenges in Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Perioperative Period; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamole; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Thiazoles; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Warfarin | 2017 |
[State of the art: Direct oral anticoagulants and transfusion].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia | 2017 |
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Myocardial Infarction; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thrombosis; Vitamin K | 2017 |
Reversal agents for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Hematoma; Humans; Mortality; Odds Ratio; Phenprocoumon; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Thiazoles; Vitamin K; Warfarin | 2018 |
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Benzamides; Blood Loss, Surgical; Dabigatran; Deprescriptions; Elective Surgical Procedures; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
An update on the bleeding risks associated with DOACs.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2017 |
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2018 |
Direct oral anticoagulants: An update.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment | 2018 |
Novel oral anticoagulants in the preoperative period: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Preoperative Period; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2018 |
Advances in anticoagulation therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thrombosis | 2018 |
[Antidote treatment during use of direct anticoagulants].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles | 2018 |
Review: An overview and analysis of novel oral anticoagulants and their dental implications.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dental Care; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2018 |
Novel oral anticoagulants in chronic kidney disease: ready for prime time?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Venous Thromboembolism | 2018 |
Update on Direct Oral AntiCoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Drug Substitution; Heparin, Low-Molecular-Weight; Humans; Kidney Function Tests; Liver Function Tests; Metabolic Clearance Rate; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Case-Control Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2019 |
A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Ventricular Dysfunction, Left | 2018 |
[Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Blood Coagulation Tests; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Premedication; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism | 2018 |
A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Heart Transplantation; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2018 |
A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Bayes Theorem; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Treatment Outcome | 2018 |
Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cyclophosphamide; Dabigatran; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Male; Multimorbidity; Obesity; Prognosis; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Assessment; Rivaroxaban; Thromboembolism | 2018 |
Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enzymes; Humans; Pharmacogenomic Testing; Pharmacogenomic Variants; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2018 |
Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2018 |
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Warfarin | 2019 |
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).
Topics: Ambulatory Care; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Neoplasms; Patient Discharge; Patient Selection; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Substance Abuse, Intravenous; Thiazoles | 2018 |
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2018 |
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
Insights From Practice With Use of Direct Oral Anticoagulants in Transplantation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Organ Transplantation; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism | 2018 |
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Topics: Administration, Intravenous; Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Tissue Plasminogen Activator | 2018 |
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Sweden; Thiazoles; Warfarin | 2018 |
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Thiazoles; Thromboembolism; Warfarin | 2018 |
Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal.
Topics: Anticoagulants; Dabigatran; Drug Hypersensitivity; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; Warfarin | 2019 |
Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thromboembolism; Time Factors | 2018 |
Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2019 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
Atrial Fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2019 |
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Reversing Direct Oral Anticoagulants in Acute Intracranial Hemorrhage.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Dabigatran; Humans; Intracranial Hemorrhages; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism; Treatment Outcome | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
[Dermatosurgery in the age of novel oral anticoagulants/direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dermatologic Surgical Procedures; Humans; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke; Survival Analysis; Thiazoles; Vitamin K | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2020 |
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism | 2020 |
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations.
Topics: Anticoagulants; Body Weight; Dabigatran; Drug Dosage Calculations; Factor Xa Inhibitors; Humans; Obesity; Overweight; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Consensus Development Conferences as Topic; Dabigatran; Europe; Female; Humans; Long-Term Care; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Periprocedural Management of Oral Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Surgical Procedures, Operative; Warfarin | 2020 |
Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review.
Topics: Dabigatran; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Humans; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Treatment Outcome | 2020 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
[Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility].
Topics: Administration, Oral; Age Factors; Aged; Antithrombins; Dabigatran; Frail Elderly; Humans; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Venous Thromboembolism | 2020 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Liver Diseases; Pyrazoles; Pyridones; Stroke | 2021 |
Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Topics: Animals; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Platelet Activation; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome | 2020 |
Direct oral anticoagulants: evidence and unresolved issues.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin | 2021 |
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Italy; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2021 |
Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Observational Studies as Topic; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
Direct oral anticoagulant safety during breastfeeding: a narrative review.
Topics: Anticoagulants; Breast Feeding; Dabigatran; Factor Xa Inhibitors; Female; Humans; Milk, Human; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2021 |
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Comparison of non-vitamin K antagonist oral anticoagulants on bleeding and thrombosis.
Topics: Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2021 |
Direct oral anticoagulants for use in paediatrics.
Topics: Antithrombins; Child; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pediatrics; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2022 |
Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Incidence; Japan; Product Surveillance, Postmarketing; Pyridones; Rivaroxaban; Stroke | 2023 |
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Pyridones; Rheumatic Heart Disease; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2023 |
Altered plasma levels of apixaban in major gastrointestinal tract surgery: A case report and review of the literature.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Tract; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
24 trial(s) available for dabigatran and apixaban
| Article | Year |
|---|---|
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospitals, University; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2012 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Monitoring; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism | 2016 |
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Topics: Administration, Oral; Anticoagulants; Arrhythmias, Cardiac; Canada; Cause of Death; Dabigatran; Defibrillators, Implantable; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Pacemaker, Artificial; Practice Guidelines as Topic; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2016 |
Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Point-of-Care Systems; Prospective Studies; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Thrombin Time | 2017 |
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2017 |
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Canada; Cardiac Surgical Procedures; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Perioperative Period; Postoperative Complications; Precision Medicine; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Body Mass Index; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obesity; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrazoles; Pyridones; Rivaroxaban | 2018 |
Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pacemaker, Artificial; Pilot Projects; Prospective Studies; Prosthesis Implantation; Pyrazoles; Pyridones; Rivaroxaban; Single-Blind Method; Warfarin | 2018 |
Differences between activities of coagulation factors after one month of therapy with different direct oral anticoagulant in pulmonary embolism patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Blood Coagulation Factors; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thrombin; Treatment Outcome | 2019 |
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Drug Administration Schedule; Female; Hematoma; Humans; Length of Stay; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Reoperation; Rivaroxaban; Thromboembolism | 2018 |
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Whole Blood Coagulation Time | 2019 |
Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.
Topics: Action Potentials; Aged; Antithrombins; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2019 |
MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists.
Topics: Aged; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Reperfusion; Rivaroxaban; Stroke; Thrombectomy; Treatment Outcome; Vitamin K | 2020 |
Body weight is negatively associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users.
Topics: Administration, Oral; Aged; Anticoagulants; Body Weight; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones | 2020 |
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Topics: Aged; Angiotensin-Converting Enzyme 2; Antithrombins; Atrial Fibrillation; Betacoronavirus; Biomarkers; Cohort Studies; Coronavirus Infections; COVID-19; Dabigatran; Female; Humans; Male; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazoles; Pyridones; Risk Factors; SARS-CoV-2; Stroke; Warfarin | 2020 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
CytoSorb haemoadsorption for removal of apixaban-A proof-of-concept pilot case for a randomized controlled trial.
Topics: Anticoagulants; Dabigatran; Humans; Pyridones; Rivaroxaban | 2022 |
Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Hemorrhage; Humans; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
543 other study(ies) available for dabigatran and apixaban
| Article | Year |
|---|---|
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Topics: Animals; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Morpholines; Pyrazoles; Pyridines; Pyridones; Rabbits; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2009 |
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2011 |
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
New antithrombotic drugs and European approval processes.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Europe; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
["Xa-tra-xa": opportunities and open questions about new anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
The new oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2011 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
[Anticoagulation in atrial fibrillation: a new era has begun].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Approval; Humans; Kidney; Liver; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; United States; United States Food and Drug Administration | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2012 |
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
Danger ahead: watch out for indirect comparisons!
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
[Role of new oral anticoagulants in interventional cardiology].
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cardiac Surgical Procedures; Cardiology; Dabigatran; Humans; Morpholines; Percutaneous Coronary Intervention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Europe; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Patient Selection; Preventive Health Services; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Extended treatment of venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Antidotes edge closer to reversing effects of new blood thinners.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Humans; Pyrazoles; Pyridones; Recombinant Proteins; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1 | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Perioperative management of patients who are receiving a novel oral anticoagulant.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
[New oral anticoagulants in nonvalvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
[New direct oral anticoagulants and venous thromboprophylaxis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Germany; Humans; Male; Models, Econometric; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
How I treat target-specific oral anticoagulant-associated bleeding.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Factor VIIa; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time | 2014 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/+) mice.
Topics: Age Factors; Animals; Benzimidazoles; Clopidogrel; Dabigatran; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Genes, APC; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrazoles; Pyridines; Pyridones; Risk Factors; Ticlopidine; Warfarin | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Dabigatran; Humans; Mass Spectrometry; Molecular Structure; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Urologic Surgical Procedures | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Direct oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Ischemia; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Economics, Pharmaceutical; Enoxaparin; Models, Economic; Pyrazoles; Pyridones; Rivaroxaban; Spain; Treatment Outcome; Venous Thromboembolism | 2014 |
Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor Xa; Humans; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Thrombelastography; Thrombin | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Outcome following intracranial hemorrhage associated with novel oral anticoagulants.
Topics: Aged, 80 and over; Anticoagulants; Antidotes; Blood Coagulation Tests; Dabigatran; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Neurologic Examination; Pyrazoles; Pyridones; Rivaroxaban; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Quality Control; Reference Values; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Laboratory monitoring of the non-vitamin K oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Sex Factors; Stroke | 2015 |
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2014 |
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Databases, Factual; Decision Support Techniques; Female; Hemorrhage; Humans; Male; Managed Care Programs; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Stroke; United States | 2014 |
Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Feeding Behavior; Female; Glomerular Filtration Rate; Humans; Male; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2015 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Dipeptides; Enzyme Assays; Factor Xa Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Whole Blood Coagulation Time | 2015 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2014 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2015 |
Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Defibrillators, Implantable; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Are new oral anticoagulant dosing recommendations optimal for all patients?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
[Prospective study of the new oral anticoagulants in private practice: cautious optimism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiology; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Female; France; General Practice; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Surveys and Questionnaires; Thromboembolism; Treatment Outcome | 2015 |
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2015 |
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Germany; Humans; Pyrazoles; Pyridines; Pyridones; Quality of Life; Quality-Adjusted Life Years; Rivaroxaban; Thiazoles; Warfarin | 2015 |
Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Decision Support Techniques; Embolism; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.
Topics: Administration, Oral; Anticoagulants; Chromatography, Liquid; Dabigatran; Humans; Pyrazoles; Pyridones; Quality Control; Rivaroxaban; Tandem Mass Spectrometry; Vitamin K | 2015 |
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombelastography; Venous Thromboembolism; Young Adult | 2015 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2015 |
National Trends in Ambulatory Oral Anticoagulant Use.
Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; United States; Venous Thromboembolism; Warfarin; Young Adult | 2015 |
Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Patient Admission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2015 |
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Topics: Anticoagulants; Chromogenic Compounds; Dabigatran; Enzyme Assays; Factor Xa Inhibitors; Humans; Laboratories; Point-of-Care Systems; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pharmaceutical Services; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2015 |
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Audit; Dabigatran; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Point-of-Care Testing; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2015 |
Direct oral anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Drug Costs; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2015 |
[New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Utilization; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombophilia; Urban Health Services | 2016 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Dabigatran; Dipyridamole; Female; Guideline Adherence; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Ticlopidine; Warfarin | 2015 |
Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Greece; Health Care Costs; Humans; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2015 |
Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2015 |
Management of acute pulmonary embolism.
Topics: Acute Disease; Age Factors; Ambulatory Care; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Disease Management; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Male; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thrombolytic Therapy; Tissue Plasminogen Activator; Vena Cava Filters; Warfarin | 2015 |
Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Topics: Action Potentials; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Electrophysiologic Techniques, Cardiac; Factor Xa Inhibitors; Female; Heart Rate; Humans; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2016 |
Direct oral anticoagulants and the bleeding patient.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Charcoal; Dabigatran; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Tranexamic Acid; Warfarin | 2016 |
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2015 |
Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Component Transfusion; Coronary Artery Bypass; Dabigatran; Drug Costs; Female; Humans; Length of Stay; Male; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2015 |
Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities.
Topics: Adult; Age Factors; Anticoagulants; Child; Child, Preschool; Clinical Trials as Topic; Dabigatran; Disease Management; Evidence-Based Medicine; Heparin, Low-Molecular-Weight; Humans; Infant; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Emergency admissions for major haemorrhage associated with direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Gastrointestinal Hemorrhage; Hemodynamics; Hemorrhage; Hemostasis; Humans; Intracranial Hemorrhages; Male; Middle Aged; Patient Admission; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thrombosis | 2015 |
Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardio-Renal Syndrome; Contraindications; Creatinine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Portugal; Pyrazoles; Pyridones; Stroke; Warfarin | 2015 |
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Canada; Dabigatran; Female; Guidelines as Topic; Humans; Internship and Residency; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Surveys and Questionnaires; Treatment Outcome; Universities; Warfarin | 2016 |
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2016 |
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Rivaroxaban; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Warfarin | 2016 |
[Your patient needs an antithrombotic drug. Venous thrombosis of the leg: how and how long anticoagulation?].
Topics: Administration, Oral; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Fibrinolytic Agents; General Practice; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thrombosis | 2015 |
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2016 |
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Patient Compliance; Pyrazoles; Pyridones; Retrospective Studies; Stroke; Surveys and Questionnaires; Treatment Outcome; Warfarin | 2016 |
Direct new oral anticoagulants in the emergency department: Experience in everyday clinical practice at a Swiss university hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Hospitals, University; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Switzerland | 2016 |
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry | 2016 |
Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dental Care; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Carboxypeptidase B2; Dabigatran; Factor Xa Inhibitors; Female; Fibrinolysis; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thrombin | 2016 |
An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm.
Topics: Administration, Oral; Anticoagulants; Attitude of Health Personnel; Blood Coagulation; Blood Coagulation Tests; Cardiology; Dabigatran; Electronic Health Records; Health Knowledge, Attitudes, Practice; Humans; Patient Harm; Patient Safety; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Surveys and Questionnaires; United Kingdom | 2016 |
Uptake of novel oral anticoagulants in Australia.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Veterans | 2016 |
Direct oral anticoagulants in rare venous thrombosis.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Venous Thrombosis | 2016 |
The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Cryosurgery; Dabigatran; Female; Germany; Humans; Incidence; Inflammation Mediators; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pulmonary Veins; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2016 |
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Topics: Anticoagulants; Blood Coagulation Tests; Blood Donors; Calibration; Dabigatran; Enoxaparin; Factor X; Female; Fondaparinux; Heparin; Humans; International Normalized Ratio; Male; Polysaccharides; Prothrombin; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thromboplastin; Warfarin | 2016 |
Direct oral anticoagulant drugs (DOAC).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Loss, Surgical; Cataract Extraction; Dabigatran; Eye Hemorrhage; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Heavy menstrual bleeding on Rivaroxaban - Comparison with Apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Loss, Surgical; Cerebral Hemorrhage; Clinical Trials as Topic; Dabigatran; Drug Approval; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2016 |
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Australia; Dabigatran; Drug Prescriptions; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2016 |
Which oral anticoagulant for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Patient Selection; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2016 |
Lupus-anticoagulant testing at NOAC trough levels.
Topics: Administration, Oral; Adult; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Humans; Insurance, Health; Middle Aged; Models, Theoretical; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2016 |
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Young Adult | 2016 |
Anticoagulants: What is new and what is the standard?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dementia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pipecolic Acids; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Sulfonamides; Venous Thrombosis | 2016 |
Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2016 |
Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Hematoma; Hospital Mortality; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Tomography, X-Ray Computed; Warfarin | 2016 |
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism | 2016 |
Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Female; Humans; Hyphema; Male; Pyrazoles; Pyridones; Retinal Hemorrhage; Rivaroxaban; Vitreous Hemorrhage | 2017 |
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Italy; Logistic Models; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Vitamin K | 2016 |
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Connecticut; Dabigatran; Demography; Factor Xa Inhibitors; Female; Humans; Injury Severity Score; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Trauma Centers; Warfarin; Wounds and Injuries | 2016 |
Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Denmark; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2016 |
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiac Surgical Procedures; Dabigatran; Emergencies; Female; Gastrointestinal Hemorrhage; Heart Transplantation; Hemorrhage; Hemostatics; Heparin; Humans; Incidence; International Normalized Ratio; Intracranial Hemorrhages; Laparotomy; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Thrombocytopenia; Thromboembolism; Vitamin K; Warfarin | 2016 |
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; United States; Warfarin; Young Adult | 2016 |
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Calibration; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Italy; Male; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Regression Analysis; Rivaroxaban; Thrombin Time; Treatment Outcome | 2016 |
Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Warfarin | 2016 |
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles | 2016 |
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Norway; Prescription Drugs; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2017 |
Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Internet; Patient Education as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2016 |
[Safer treatment with serum concentration monitoring of the new anticoagulants?].
Topics: Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Pyrazoles; Pyridones; Reference Standards; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Denmark; Female; Hospitalization; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
Topics: Anticoagulants; Blood Coagulation Tests; Calibration; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Sensitivity and Specificity | 2016 |
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Follow-Up Studies; Humans; Insurance Claim Review; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States | 2016 |
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Patient Readmission; Percutaneous Coronary Intervention; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stents; Stroke; Thrombosis; Venous Thromboembolism; Warfarin | 2016 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
[Gastrointestinal bleeding during treatment with nonvitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Pilot Projects; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Drug Stability; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
Topics: Administration, Oral; Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Dose-Response Relationship, Drug; Humans; Limit of Detection; Prodrugs; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban | 2017 |
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Emergency Treatment; Female; Humans; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pyrazoles; Pyridines; Pyridones; Quality Improvement; Registries; Rivaroxaban; Stroke; Thiazoles; United States; Warfarin | 2016 |
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States | 2016 |
Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Taiwan; Warfarin | 2017 |
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Vitamin K; Young Adult | 2017 |
Risk of intraocular hemorrhage with new oral anticoagulants.
Topics: Anticoagulants; Dabigatran; Eye Hemorrhage; Humans; Ocular Hypertension; Odds Ratio; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2017 |
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease.
Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazoles; Pyridones; Thrombosis | 2017 |
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2017 |
Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.
Topics: Administration, Oral; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Child; Child, Preschool; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin; World Health Organization; Young Adult | 2017 |
Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.
Topics: Adult; Anticoagulants; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thrombophilia; Venous Thromboembolism; Young Adult | 2017 |
[Monitoring of NOAC].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Emergency Service, Hospital; Hemorrhage; Humans; Intensive Care Units; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Hospital Mortality; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Recombinant Proteins; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Warfarin | 2017 |
Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Automation, Laboratory; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Female; Humans; Ischemic Attack, Transient; Male; Microfluidic Analytical Techniques; Microscopy, Fluorescence; Middle Aged; Phenprocoumon; Predictive Value of Tests; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2017 |
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2017 |
[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Electric Countershock; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Intensive Care Units; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin; Thromboembolism; Vitamin K | 2017 |
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antithrombins; Blood Coagulation; Brain Ischemia; Dabigatran; Databases, Factual; Drug Approval; Factor Xa Inhibitors; Female; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome | 2017 |
Italian intersociety consensus on DOAC use in internal medicine.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism | 2017 |
Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Data Collection; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Observational Studies as Topic; Patient Selection; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke; Warfarin | 2017 |
A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Transfusion; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Incidence; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin | 2017 |
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system.
Topics: Adult; Anticoagulants; Antithrombins; Automation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Limit of Detection; Male; Middle Aged; Point-of-Care Systems; Pyrazoles; Pyridones; Rivaroxaban; Thrombelastography | 2017 |
[Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Markov Chains; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2017 |
[Real-world data on novel oral anticoagulants: the added value of registries and observational studies. Focus on apixaban].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Observational Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke | 2016 |
Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
Topics: Administration, Oral; Aged; Antithrombins; Blood Coagulation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Time Factors; Treatment Outcome; Venous Thromboembolism | 2017 |
Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2017 |
[Incidence, investigation and long-term follow-up of macroscopic hematuria in patients treated with non vitamin K antagonist oral anticoagulant: Insight from a specialist cardiology clinic].
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Factor Xa Inhibitors; Female; Follow-Up Studies; Hematuria; Humans; Kidney Calculi; Male; Neoplasms; Prostatic Hyperplasia; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2017 |
Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation; Cerebral Hemorrhage; Chi-Square Distribution; Cross-Sectional Studies; Dabigatran; Disability Evaluation; Factor Xa Inhibitors; Female; Hematoma; Humans; Japan; Linear Models; Male; Middle Aged; Multivariate Analysis; Patient Discharge; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Tomography, X-Ray Computed; Treatment Outcome; Warfarin | 2017 |
Trends in the prescription of novel oral anticoagulants in UK primary care.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; United Kingdom; Vitamin K | 2017 |
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Cohort Studies; Dabigatran; Europe; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2017 |
Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Comorbidity; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dabigatran; Female; Humans; Injury Severity Score; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Ticlopidine; Trauma Centers; Warfarin; Wounds and Injuries; Wounds, Nonpenetrating | 2017 |
A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Postoperative Complications; Pyrazoles; Pyridones; Thrombosis; Treatment Outcome | 2017 |
Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban.
Topics: Animals; Anticoagulants; Biological Transport; Dabigatran; Drug Interactions; Female; Haplorhini; HEK293 Cells; Humans; Kidney; Mice; Mice, Inbred C57BL; Organic Anion Transporters; Pyrazoles; Pyridones; Rats; Rats, Sprague-Dawley; Rivaroxaban | 2017 |
Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Antithrombotic Therapy for Venous Thromboembolic Disease.
Topics: Antithrombins; Dabigatran; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Review Literature as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Topics: Ablation Techniques; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Belgium; Cryosurgery; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Intraoperative Period; Italy; Male; Middle Aged; Postoperative Complications; Prognosis; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thiazoles; Time Factors; Vitamin K | 2017 |
Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Thromboembolism; Time Factors; Treatment Outcome | 2017 |
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Vitamin K; Young Adult | 2017 |
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Expenditures; Health Resources; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban | 2017 |
Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2017 |
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Substitution; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2018 |
Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Platelet Count; Pyrazoles; Pyridones; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2017 |
Choice of oral anticoagulants in older patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles; Warfarin | 2017 |
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2017 |
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2017 |
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Norway; Pyrazoles; Pyridones; Rivaroxaban; Warfarin; Young Adult | 2017 |
The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hospitalization; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban | 2017 |
Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Utilization; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Scotland; Warfarin | 2017 |
New oral anticoagulant prescription rate and risk of bleeding in an Italian region.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Cross-Over Studies; Dabigatran; Drug Prescriptions; Female; Hemorrhage; Hospitalization; Humans; Italy; Male; Middle Aged; Prevalence; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Time Factors | 2017 |
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Topics: Aged; Aged, 80 and over; Antithrombins; Blood Coagulation Disorders; Blood Coagulation Tests; Dabigatran; Emergencies; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thrombin Time; Thrombolytic Therapy | 2017 |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System.
Topics: Administration, Oral; Aged; Anticoagulants; Area Under Curve; Atrial Fibrillation; Dabigatran; Female; Humans; Lab-On-A-Chip Devices; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2017 |
Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Measuring Direct Oral Anticoagulants.
Topics: Administration, Oral; Antithrombins; Blood Coagulation; Dabigatran; Drug Monitoring; Endopeptidases; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time; Venous Thromboembolism | 2017 |
New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Diet; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
In nonvalvular AF, DOAC-related risk for GI bleeding was lower with apixaban than dabigatran or rivaroxaban.
Topics: Benzimidazoles; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Prescriptions; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Warfarin | 2017 |
Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Cardiac Catheters; Cerebrovascular Disorders; Cryosurgery; Dabigatran; Drug Administration Schedule; Drug Monitoring; Equipment Design; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2017 |
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2017 |
Direct oral anticoagulant medications in calciphylaxis.
Topics: Adult; Aged; Anticoagulants; Calciphylaxis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban | 2017 |
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke | 2018 |
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Drug Prescriptions; Factor Xa Inhibitors; Female; Humans; Linear Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health | 2017 |
Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.
Topics: Administration, Oral; Adult; Age Factors; Aged; Algorithms; Anticoagulants; Cohort Studies; Dabigatran; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis | 2017 |
Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Topics: Anticoagulants; Antithrombins; Dabigatran; France; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Turkey | 2018 |
Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2017 |
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Mohs Surgery; Postoperative Complications; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2017 |
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Stroke; Thiazoles | 2018 |
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiovascular Diseases; Clinical Decision-Making; Dabigatran; Drug Monitoring; Drug Resistance; Factor Xa Inhibitors; Focus Groups; General Practitioners; Hemorrhage; Humans; Medical Staff, Hospital; Medication Adherence; Norway; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Qualitative Research; Risk; Rivaroxaban; Warfarin | 2018 |
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; International Normalized Ratio; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2017 |
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Arteriovenous Malformations; Aspirin; Blood Transfusion; Case-Control Studies; Dabigatran; Diverticulum; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Hemorrhoids; Hospitalization; Humans; Male; Middle Aged; Peptic Ulcer; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2018 |
Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Inappropriate Prescribing; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2018 |
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Vitamin K | 2017 |
[Stroke after discontinuation of new anticoagulants prior to surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Stroke; Surgical Procedures, Operative; Time Factors; Tomography, X-Ray Computed | 2017 |
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Outpatients; Patient Discharge; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
Topics: Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Venous Thrombosis; Warfarin | 2018 |
Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dabigatran; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Chronic Disease; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Thiazoles; Treatment Outcome; Ultrasonography; Venous Thrombosis; Warfarin | 2018 |
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Synergism; Hemorrhage; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Taiwan | 2018 |
Effects of Direct Oral Anticoagulants at the Peak Phase, Trough Phase, and After Vascular Injury.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Punctures; Pyrazoles; Pyridones; Rivaroxaban; Vascular System Injuries; Warfarin | 2018 |
Bleeding Complications After Use of Novel Oral Anticoagulants in Patients Undergoing Cardiac Surgery.
Topics: Aged; Anticoagulants; Blood Transfusion; Cardiac Surgical Procedures; Critical Care; Dabigatran; Female; Heart Diseases; Humans; Length of Stay; Male; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Rivaroxaban | 2018 |
Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Emergency Treatment; Humans; Partial Thromboplastin Time; Pyrazoles; Pyridones; Reference Values; Rivaroxaban; Sensitivity and Specificity; Thrombin Time | 2018 |
Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Tests; Calibration; Clinical Laboratory Services; Dabigatran; Humans; International Normalized Ratio; Italy; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Quality Control; Reproducibility of Results; Rivaroxaban; Surveys and Questionnaires; Thrombin Time | 2018 |
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2018 |
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Dabigatran; Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Survival Analysis; Venous Thrombosis; Warfarin | 2018 |
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Drug Prescriptions; Drug Substitution; Female; France; Humans; Male; Primary Health Care; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2018 |
Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Fibrin Clot Lysis Time; Heparin, Low-Molecular-Weight; Humans; Linear Models; Male; Middle Aged; Phenprocoumon; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Thromboplastin; Tissue Plasminogen Activator | 2018 |
Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Kidney Function Tests; Male; Multivariate Analysis; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Registries; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke | 2018 |
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Chromatography; Clinical Laboratory Techniques; Dabigatran; Hematology; Humans; International Cooperation; Mass Spectrometry; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Quality Assurance, Health Care; Rivaroxaban; Thiazoles | 2018 |
Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Preliminary Data; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Topics: Antithrombins; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles | 2018 |
Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Utilization Review; Female; Humans; Male; Medication Adherence; Middle Aged; Netherlands; Pyrazoles; Pyridones; Rivaroxaban; Sweden; Thromboembolism | 2018 |
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Contrast Media; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Factor Xa Inhibitors; Female; Heart Atria; Heart Diseases; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis | 2018 |
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Taiwan; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Frail Elderly; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Warfarin | 2018 |
Management of oral anticoagulation in patients with atrial fibrillation: newer agents, newer conundrums?
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Microbleeds in ischemic vs hemorrhagic strokes on novel oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Comorbidity; Dabigatran; Female; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombolytic Therapy | 2018 |
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; United States; Warfarin | 2018 |
Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Warfarin; Withholding Treatment; Young Adult | 2018 |
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Models, Statistical; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2018 |
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2018 |
Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Caregivers; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Self Report; Thiazoles | 2018 |
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban; Treatment Outcome; Ventricular Fibrillation | 2018 |
Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antithrombins; Chronic Disease; Dabigatran; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Reproducibility of Results; Treatment Outcome; Vitamin K | 2018 |
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2018 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Humans; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrazoles; Pyridones; Republic of Korea; Rivaroxaban; Warfarin | 2018 |
Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke pre
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Inappropriate Prescribing; Male; Medical Audit; Middle Aged; Prescriptions; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2019 |
NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Humans; Incidence; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thrombolytic Therapy; Treatment Outcome; Victoria; Warfarin | 2019 |
Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Quebec; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2018 |
Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Dementia; Dicumarol; Disabled Persons; Follow-Up Studies; Hemorrhage; Humans; Mobility Limitation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2018 |
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome | 2018 |
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Patient Safety; Primary Health Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Germany; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation Inhibitors; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke | 2018 |
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Israel; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
Topics: Anticoagulants; Automation; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Solid Phase Extraction; Tandem Mass Spectrometry; Thiazoles | 2018 |
Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Databases, Factual; Female; Humans; Male; Norway; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Factors; Stroke | 2018 |
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Databases, Factual; Drug Dosage Calculations; Female; Hemorrhage; Humans; Inappropriate Prescribing; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Prevalence; Pyrazoles; Pyridines; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Obesity, Morbid; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2019 |
Anticoagulant-associated adverse drug reactions in 2013-15.
Topics: Age Distribution; Anticoagulants; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Distribution; Time Factors; Warfarin | 2018 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2019 |
Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Drug Interactions; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2018 |
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2019 |
[Evaluation of adverse drug reactions associated with direct oral anticoagulants recorded in the Italian Pharmacovigilance Network database using a specifically developed risk index].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Italy; Pharmacovigilance; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles | 2018 |
A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Female; Humans; Linear Models; Male; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Comparison between specific and nonspecific assay in the evaluation of the anticoagulant effect of the Direct Oral Anticoagulants: Our experience in a cardiovascular hospital.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Platelet Membrane Glycoproteins; Pyrazoles; Pyridones; Rivaroxaban | 2019 |
Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Prothrombin Time; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thrombin; Venous Thrombosis | 2018 |
The risk of delayed intracranial hemorrhage with direct acting oral anticoagulants after trauma: A two-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain; Brain Injuries, Traumatic; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Neuroimaging; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Time Factors; Tomography, X-Ray Computed | 2019 |
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2019 |
Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Angiography; Dabigatran; Diffusion Magnetic Resonance Imaging; Female; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Logistic Models; Magnetic Resonance Angiography; Male; Multivariate Analysis; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2018 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2018 |
Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Topics: Administration, Oral; Aged; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Thrombolytic Therapy | 2018 |
Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Coronary Thrombosis; Dabigatran; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2019 |
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Inpatients; Male; Middle Aged; Outpatients; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2018 |
Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hip Fractures; Humans; Male; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2019 |
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles | 2018 |
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Scotland; Stroke; Treatment Outcome | 2019 |
Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Female; Gastrointestinal Diseases; Humans; Incidence; Male; Middle Aged; Netherlands; Proportional Hazards Models; Proton Pump Inhibitors; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke | 2018 |
Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Progression; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Korea; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2018 |
Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Coagulants; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Young Adult | 2019 |
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Adherence and Compliance; United States; Warfarin | 2019 |
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Military Medicine; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Defense; Young Adult | 2019 |
Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Retrospective Studies; Rivaroxaban; Thrombelastography; Treatment Outcome | 2019 |
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Upper Gastrointestinal Tract; Warfarin | 2018 |
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles | 2018 |
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Topics: Anticoagulants; Antithrombins; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time | 2018 |
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2018 |
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Craniocerebral Trauma; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2019 |
Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Middle Aged; Odds Ratio; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin; Young Adult | 2019 |
Assessment of direct oral anticoagulant assay use in clinical practice.
Topics: Anticoagulants; Dabigatran; Decision Making; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Surgical Procedures, Operative | 2019 |
Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment.
Topics: Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Dabigatran; Female; Hematoma; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2019 |
Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Italy; Male; Propensity Score; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Spain; Stroke; Thiazoles; Treatment Outcome | 2019 |
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles | 2019 |
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Dabigatran; Humans; Infusions, Intravenous; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Pyrazoles; Pyridones; Risk Assessment; Thromboembolism; Tranexamic Acid; Venous Thrombosis | 2019 |
Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Utilization Review; Female; Humans; Israel; Male; Medical Overuse; Pharmacists; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2019 |
Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin | 2019 |
The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; False Positive Reactions; Female; Humans; Lupus Coagulation Inhibitor; Male; Middle Aged; Partial Thromboplastin Time; Plasma; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2019 |
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.
Topics: Administration, Oral; Anticoagulants; Austria; Brain Injuries, Traumatic; Consensus; Dabigatran; Deamino Arginine Vasopressin; Humans; Interdisciplinary Communication; Partial Thromboplastin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Tomography, X-Ray Computed; Tranexamic Acid; Treatment Outcome; Vitamin K | 2019 |
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Drug Labeling; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Risk Factors; Rivaroxaban; Thiazoles; Vitamin K | 2019 |
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Polish regional differences in patient knowledge on atrial fibrillation and its management as well as in patterns of oral anticoagulant prescription.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Management; Female; Hospitals, District; Hospitals, Teaching; Humans; Male; Patient Education as Topic; Patient Medication Knowledge; Poland; Pyrazoles; Pyridones; Rivaroxaban; Surveys and Questionnaires | 2019 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2019 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review.
Topics: Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2019 |
Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Administration Schedule; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2019 |
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Withholding Treatment | 2019 |
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Geriatrics; Germany; Humans; Middle Aged; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K | 2019 |
[One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Humans; Hungary; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Vitamin K | 2019 |
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Heart Failure; Humans; Incidence; Kaplan-Meier Estimate; Male; Medicare; Patient Safety; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; United States; Warfarin | 2019 |
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Treatment Outcome | 2019 |
Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Australia; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Myocardial Infarction; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Veterans; Warfarin | 2019 |
Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Statistics, Nonparametric; Treatment Outcome | 2019 |
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus.
Topics: Adult; Aged; Blood Transfusion; Dabigatran; Echocardiography; Epistaxis; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Ventricles; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Ventricular Dysfunction, Left | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; United States Department of Defense; Warfarin; Young Adult | 2019 |
Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Patients; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Safety | 2019 |
Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Denmark; Dose-Response Relationship, Drug; Drug Interactions; Drug Utilization; Female; France; Germany; Humans; Longitudinal Studies; Male; Metalloporphyrins; Middle Aged; Netherlands; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Spain; United Kingdom; Young Adult | 2019 |
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Denmark; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Pyrazoles; Pyridones; Rivaroxaban; United States; Vitamin K; Warfarin | 2019 |
Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.
Topics: Anticoagulants; Australia; Cross-Sectional Studies; Dabigatran; Drug Industry; Education, Medical, Continuing; Humans; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban | 2019 |
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
Topics: Aged; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles | 2019 |
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Epistaxis; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Telangiectasia, Hereditary Hemorrhagic; Venous Thromboembolism; Warfarin | 2019 |
Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Thrombelastography | 2020 |
The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Blood Cell Count; Blood Coagulation Tests; Chronic Disease; Creatinine; Dabigatran; Drug Prescriptions; Female; France; Humans; Kidney Function Tests; Male; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban | 2020 |
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United Kingdom | 2019 |
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Kidney Diseases; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; United Kingdom | 2019 |
Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Blood Loss, Surgical; Dabigatran; Eye Hemorrhage; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Israel; Male; Middle Aged; Phacoemulsification; Postoperative Hemorrhage; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism | 2019 |
NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surveys and Questionnaires; Thiazoles | 2020 |
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2020 |
Detecting direct oral anticoagulants in trauma patients using liquid chromatography-mass spectrometry: A novel approach to medication reconciliation.
Topics: Administration, Oral; Aged; Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Female; Healthy Volunteers; Humans; Male; Mass Spectrometry; Medication Reconciliation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Wounds and Injuries | 2020 |
Hematoma Risk After Needle Electromyography in Patients Using Newer Oral Anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Electromyography; Female; Hematoma; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2021 |
Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Female; Fractures, Bone; Hip Fractures; Hospitalization; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Protective Factors; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2020 |
Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Taiwan; Warfarin | 2020 |
Optimization by response surface methodology of a dispersive magnetic solid phase extraction exploiting magnetic graphene nanocomposite coupled with UHPLC-PDA for simultaneous determination of new oral anticoagulants (NAOs) in human plasma.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Graphite; Humans; Limit of Detection; Magnetite Nanoparticles; Nanocomposites; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Solid Phase Extraction | 2020 |
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2020 |
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin; Young Adult | 2020 |
Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots.
Topics: Administration, Oral; Anticoagulants; Blood Volume; Chromatography, Liquid; Dabigatran; Dried Blood Spot Testing; Humans; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Vitamin K | 2020 |
Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Osteoporosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Taiwan; Treatment Outcome; Warfarin | 2020 |
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Patient Safety; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2020 |
[Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cause of Death; Comorbidity; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2020 |
Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Obesity, Morbid; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2020 |
Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; Dabigatran; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Solid Phase Extraction; Spectrophotometry; Thiazoles | 2020 |
Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Glasgow Outcome Scale; Humans; Intracranial Hemorrhage, Traumatic; Length of Stay; Male; Middle Aged; Mortality; Neurosurgical Procedures; Plasma; Platelet Transfusion; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2020 |
Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
Topics: Anticoagulants; Chromatography, Liquid; Dabigatran; Drug Monitoring; Humans; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry | 2020 |
Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2020 |
Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Young Adult | 2019 |
Trends in anticoagulant prescribing: a review of local policies in English primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; England; Female; Humans; Male; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; State Medicine; Stroke; Thiazoles; Warfarin | 2020 |
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Disease Management; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Ischemic Stroke; Italy; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2020 |
Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Anticoagulants; Asia; Comorbidity; Cross-Sectional Studies; Dabigatran; Diabetes Mellitus; Europe; Factor Xa Inhibitors; Female; Fondaparinux; Heparin; Humans; Hypertension; Latin America; Male; Middle Aged; Middle East; Neoplasms; Postoperative Complications; Practice Patterns, Physicians'; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Wounds and Injuries | 2020 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Antithrombins; Brain Ischemia; Cause of Death; Comorbidity; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Myocardial Revascularization; Ontario; Procedures and Techniques Utilization; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Thrombophilia; Vitamin K | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2020 |
Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hip Fractures; Hong Kong; Humans; Male; Osteoporotic Fractures; Pyrazoles; Pyridones; Rivaroxaban; Spinal Fractures; Stroke; Warfarin | 2020 |
Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases.
Topics: Administration, Oral; Alopecia; Anticoagulants; Dabigatran; Data Mining; Databases, Factual; Humans; Minoxidil; Pharmacovigilance; Platelet-Rich Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2020 |
The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Prescriptions; Health Expenditures; Humans; Interrupted Time Series Analysis; Middle Aged; National Health Programs; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Republic of Korea; Retrospective Studies; Rivaroxaban | 2020 |
Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Cohort Studies; Dabigatran; Databases, Factual; Female; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Risk; Rivaroxaban; Warfarin | 2020 |
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban | 2020 |
Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thromboembolism | 2020 |
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Frail Elderly; Hemorrhage; Humans; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Vitamin K; Warfarin | 2021 |
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Topics: Administration, Oral; Aged; Anticoagulants; Bioprosthesis; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; France; Humans; Liver Failure, Acute; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Young Adult | 2020 |
A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Humans; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Endoscopic Mucosal Resection; Female; Humans; Japan; Male; Middle Aged; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stomach; Stomach Neoplasms; Thiazoles; Thromboembolism; Warfarin | 2021 |
Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study.
Topics: Aged; Aged, 80 and over; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Equipment Design; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Secondary Prevention; Stroke | 2020 |
A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Loss, Surgical; Carotid Artery Diseases; Cerebral Infarction; Dabigatran; Digestive System Surgical Procedures; Elective Surgical Procedures; Embolism; Endoscopy; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Orthopedic Procedures; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thromboembolism; Urologic Surgical Procedures; Vascular Surgical Procedures | 2020 |
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Dabigatran; Europe; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2021 |
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study.
Topics: Aged; Atrial Fibrillation; Blood Loss, Surgical; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Perioperative Care; Pyrazoles; Pyridones; Risk Adjustment; Rivaroxaban; Stroke | 2020 |
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2020 |
Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study.
Topics: Anticoagulants; Contraindications, Drug; Dabigatran; Drug Interactions; Drug Prescriptions; Drug Utilization; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dermatologic Surgical Procedures; Female; Humans; Ischemic Attack, Transient; Male; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban | 2021 |
Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Warfarin; Young Adult | 2020 |
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State.
Topics: Aged; Aged, 80 and over; Animals; Antithrombins; Arachidonic Acid; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Chlorides; Computed Tomography Angiography; Dabigatran; Deprescriptions; Factor Xa Inhibitors; Female; Ferric Compounds; Humans; Ischemic Stroke; Magnetic Resonance Angiography; Male; Mean Platelet Volume; Mice; Noxae; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Substance Withdrawal Syndrome; Thrombin; Thrombophilia; X-Ray Microtomography | 2021 |
Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Female; General Practice; Geography; Humans; Logistic Models; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Warfarin | 2021 |
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Deductibles and Coinsurance; Drug Costs; Factor Xa Inhibitors; Female; Humans; Male; Medicare Part C; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sample Size; Stroke; Thiazoles; United States; Warfarin | 2021 |
Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Mortality; Propensity Score; Pyrazoles; Pyridones; Stroke; Warfarin | 2021 |
Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome | 2021 |
Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis.
Topics: Aged; Anticoagulants; Blood Transfusion; Cohort Studies; Colonic Polyps; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hong Kong; Humans; Male; Postoperative Complications; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Rivaroxaban; Thromboembolism; Warfarin | 2022 |
Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Regression Analysis; Rivaroxaban; Warfarin | 2021 |
Comparative study of adverse drug reactions among direct-acting oral anticoagulants and vitamin K antagonists using the EudraVigilance database.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Young Adult | 2021 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |
Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Dementia; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Diabetes Mellitus; Factor Xa Inhibitors; Female; Hong Kong; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Time Factors; Treatment Outcome; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Comparative Effectiveness Research; Dabigatran; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Warfarin | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
Acute liver failure after changing oral anticoagulant from apixaban to rivaroxaban.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Liver Failure, Acute; Male; Pyrazoles; Pyridones; Rivaroxaban | 2021 |
[Is one DOAC better than another?]
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Treatment Outcome | 2021 |
How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Italy; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Surveys and Questionnaires; Thiazoles; Thrombosis; Treatment Outcome | 2021 |
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Uterine Hemorrhage; Warfarin | 2021 |
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Reduced‑dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series.
Topics: Anticoagulants; Dabigatran; Humans; Liver Cirrhosis; Pyrazoles; Pyridones; Venous Thromboembolism | 2021 |
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Incidence of abnormal uterine bleeding in a multicenter implementation study using apixaban and rivaroxaban to treat venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Female; Humans; Incidence; Pyrazoles; Pyridones; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism | 2021 |
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Treatment Outcome | 2021 |
Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Specimen Collection; Dabigatran; Humans; Middle Aged; Preservation, Biological; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2021 |
Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Frail Elderly; Humans; Male; Massachusetts; Medicare; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2021 |
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study.
Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism | 2021 |
Dabigatran-induced oesophagitis improved by switching medication to apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Esophagitis; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2021 |
The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Male; Ontario; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Warfarin | 2021 |
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Japan; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles | 2021 |
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Bariatric Surgery; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Thrombosis | 2022 |
Difference in left atrial D-dimer level in patients with atrial fibrillation treated with direct oral anticoagulant.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Biomarkers; Dabigatran; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Thiazoles; Treatment Outcome | 2021 |
Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study.
Topics: Aged; Cohort Studies; Dabigatran; Digestive System Diseases; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Iceland; Male; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Ulcer | 2021 |
Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients.
Topics: Age Factors; Aged; Aged, 80 and over; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2021 |
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2022 |
Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amyloidosis; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiomyopathies; Dabigatran; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran; Fluconazole; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Impact of different renal function equations on direct oral anticoagulant concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Creatinine; Cystatin C; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2021 |
Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; HIV Infections; Humans; Male; Pyridones; Ritonavir; Rivaroxaban; Stroke; Warfarin | 2023 |
Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes.
Topics: Anticoagulants; Dabigatran; Delivery of Health Care; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein.
Topics: Administration, Oral; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Axitinib; Crizotinib; Dabigatran; Drug Interactions; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.
Topics: Anticoagulants; Asian People; Atorvastatin; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Rivaroxaban; Simvastatin; Singapore; Stroke | 2023 |
Cutaneous Ulcer Caused by Apixaban Treatment Is Resolved after Replacement with Dabigatran.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Leg Ulcer; Pyrazoles; Pyridones; Ulcer | 2022 |
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; France; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2022 |
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cohort Studies; Dabigatran; Embolism; Humans; Ischemic Stroke; Renal Insufficiency, Chronic; Rivaroxaban; United States | 2022 |
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Thrombin | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |
Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report.
Topics: Acute Kidney Injury; Administration, Oral; Aged, 80 and over; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Male; Pyridones | 2023 |
Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |